A Phase 3 interventional study of Biological/Vaccine: BNT162b2 10mcg and BNT162b2 20mcg in SARS-CoV-2 Infection, COVID-19, sponsored by BioNTech SE. Completed at 128 sites in 6 countries. Open to participants aged 6 Months to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by BioNTech SE · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 3rd largest by enrollment, is one of 30 that started in 2021, is one of 18 in phase 3, and was the 12th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 6 Months to 15 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 30 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11,837 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one is the 4th largest by enrollment, is one of 10 that started in 2021, is one of 14 in phase 3, and was the 13th registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2/3 study in healthy children.
Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants \<6 months of age may subsequently be evaluated.
Phase 1 Dose-Finding
Is the open-label dose-finding portion of the study that will evaluate safety, tolerability, and immunogenicity of BNT162b2 administered on a 2-dose (separated by approximately 21 days) schedule in up to 3 age groups (participants ≥5 to \<12 years, ≥2 to \<5 years, and ≥6 months to \<2 years of age).
Dose finding is being initiated in this study in participants ≥5 to \<12 years of age based on the acceptable blinded safety assessment of the 30-µg dose in 12- to 15-year-olds in the C4591001 study.
The purpose of Phase 1 is to identify preferred dose level(s) of BNT162b2 from up to 3 different dose levels in each age group.
Dependent upon safety and/or immunogenicity data generated during the course of this study, it is possible that dose levels may not be started, may be terminated early, and/or may be added with dose levels below the lowest stated dose.
Update as part of protocol amendment 6: All participants will receive a third dose of BNT162b2. For participants ≥6 months to \<5 years, the third dose will occur at least 8 weeks after the second dose. In participants ≥5 to \<12 years, the third dose will occur at least 6 months after the second dose. The interval between the second and third doses will be based on the participant's age at the time of enrollment. The dose level of the third dose of BNT162b2 will be based on age at the time of vaccination: participants \<5 years of age at the time of the third dose will receive the 3-µg dose level, participants ≥5 to \<12 years of age at the time of the third dose will receive the 10-µg dose level, and participants ≥12 years of age at the time of the third dose will receive the 30-µg dose level.
Participants will have blood drawn prior to both Dose 1 and Dose 2 and 7 days after Dose 2 to assess immunogenicity to determine the selected BNT162b2 dose level for Phase 2/3. Participants will also have blood drawn prior to Dose 3 and 1, 6, and 12 months after Dose 3.
Phase 2/3 Selected-Dose
Is the portion of the study that will evaluate the safety, tolerability, and immunogenicity in each age group at the selected dose level from the Phase 1 dose-finding portion of the study. Efficacy will be evaluated within or across age groups in which immunobridging is successful, depending on accrual of a sufficient number of cases in those age groups.
Participants will have blood drawn at baseline prior to Dose 1 and 6 months after Dose 2. Immunobridging to participants 16 to 25 years of age in the C4591001 study will be based on immunogenicity data collected at (1) baseline and 1 month after Dose 2 and (2) baseline and 1 month after Dose 3. The persistence of the immune response will be based on immunogenicity data collected in participants at (1) baseline and 1 and 6 months after Dose 2 and (2) baseline and 1, 6, 12, and 18 months after Dose 3. In addition, efficacy against confirmed COVID-19 and against asymptomatic infection will also be assessed in participants ≥5 to \<12 years of age.
At designated US sites, an additional optional whole blood sample of approximately 10 mL will be obtained prior to Dose 1 and at 7 days and 6 months after Dose 2 from up to approximately 60 participants ≥10 years of age. Additional samples will be obtained prior to Dose 3 and 1 month after Dose 3 (original BNT162b2 group only). These samples will be used on an exploratory basis to investigate the postvaccination cell-mediated immune response at these time points.
At the 6-month follow-up visit, all participants will be unblinded. Participants who originally received placebo will be offered the opportunity to receive BNT162b2 as part of the study. Participants who originally received placebo and become eligible for receipt of BNT162b2 or another COVID-19 vaccine according to local or national recommendations prior to the 6 month follow-up visit (Visit 5 or 405) (detailed separately and available in the electronic study reference portal) will have the opportunity to receive BNT162b2 (10 µg or 3 µg) based on age at the time of vaccination.
Update as part of protocol amendment 6: All participants will receive a third dose of BNT162b2. For participants ≥6 months to \<5 years, the third dose will occur at least 8 weeks after the second dose. In participants ≥5 to \<12 years, the third dose will occur at least 6 months after the second dose. The interval between the second and third doses will be based on the participant's age at the time of enrollment. The dose level of the second and third doses of BNT162b2 will be based on age at the time of vaccination: participants \<5 years of age at the time of the second/third dose will receive the 3-µg dose level, participants ≥5 to \<12 years of age at the time of the second/third dose will receive the 10-µg dose level, and participants ≥12 years of age at the time of the second/third dose will receive the 30-µg dose level.
Phase 2/3 Obtaining Serum Samples for Potential Troponin I Testing
If testing of troponin I levels in individuals who did not receive BNT162b2 indicates that troponin I level could be a reliable indicator of potential subclinical myocarditis, obtaining serum samples for potential troponin I testing during the period of increased risk of clinical myocarditis may help characterize the absence/presence and frequency of subclinical myocarditis. To assess, an additional group of participants will be included: ≥5 to \<12 years: randomized 2:1 to receive BNT162b2 10 µg or placebo, and ≥12 to \<16 years of age: open-label receipt of BNT162b2 30 µg.
Update as part of protocol amendment 7: All participants will receive a third dose of BNT162b2. For all participants (≥5 to \<12 and ≥12 to \<16 years of age), the third dose will occur at least 5 months after Dose 2.
The dose level of the second and third doses of BNT162b2 will be based on age at the time of vaccination: participants ≥5 to \<12 years of age at the time of the second/third dose will receive the 10-µg dose level, and participants ≥12 years of age at the time of the second/third dose will receive the 30-µg dose level.
Update as part of protocol amendment 8: The Lower-Dose Evaluation portion of the protocol has been removed.
Participation in the study will cease 6 months after the third dose of BNT162b2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.
Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in the therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low/Mid-Dose (10mcg), 2 doses 21 days apart
Biological: Biological/Vaccine: BNT162b2 10mcg
Mid-Dose, (20mcg), 2 doses 21 days apart
Biological: BNT162b2 20mcg
High-Dose (30mcg), 2 doses 21 days apart
Biological: BNT162b2 30mcg
Low/Mid-Dose (10mcg), 2 doses 21 days apart
Biological: Biological/Vaccine: BNT162b2 10mcg
Mid-Dose, (20mcg), 2 doses 21 days apart
Biological: BNT162b2 20mcg
High-Dose, (30mcg), 2 doses 21 days apart
Biological: BNT162b2 30mcg
Low/Mid-Dose, (10mcg), 2 doses 21 days apart
Biological: Biological/Vaccine: BNT162b2 10mcg
Mid-Dose, (20mcg), 2 doses 21 days apart
Biological: BNT162b2 20mcg
High-Dose, (30mcg), 2 doses 21 days apart
Biological: BNT162b2 30mcg
Other: Placebo
Other: Placebo
Other: Placebo
Low-Dose (3mcg), 2 doses 21 doses apart
Biological: Biological/Vaccine: BNT162b2 3mcg
Low-Dose (3mcg), 2 doses 21 days apart
Biological: Biological/Vaccine: BNT162b2 3mcg
High-Dose (30mcg), 3 doses
Biological: BNT162b2 30mcg
Low/Mid-Dose (10mcg), 3 doses
Biological: Biological/Vaccine: BNT162b2 10mcg
Other: Placebo
Low-Dose (3mcg), 3 doses
Biological: Biological/Vaccine: BNT162b2 3mcg
Low-Dose (3mcg), 3 doses
Biological: Biological/Vaccine: BNT162b2 3mcg
Other: Placebo
Other: Placebo
Drug pages: Biological Products · BNT162 Vaccine
BNT162b2 Low/Mid-Dose (10mcg) level
BNT162b2 Mid-Dose (20mcg) level
BNT162b2 High-Dose (30mcg) level
Intramuscular injection
Drug pages: Biological Products · BNT162 Vaccine
BNT162b2 Low-Dose (3mcg) level
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age
Local reactions were collected in electronic diary (e-diary) or during unscheduled clinical assessments from Day 1 to 7 after Dose 1. Redness and swelling were measured and recorded in measuring device unit (mdu) where, 1 mdu = 0.5 centimeter (cm) and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 Emergency room (ER) visit or hospitalization). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% confidence interval was based on Clopper and Pearson method.
Time frame: Phase 1: From Day 1 to Day 7 after Dose 1
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 2
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 3
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 degree Celsius (deg C); categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 1
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 2
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3:>=5 to <12 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 3
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 1
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 2
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 3
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 1
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 2
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 3
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 1
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 2
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization for severe tenderness at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 3
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of Age
Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 1
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of Age
Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 2.Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake),severe (refusal to feed).Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted).Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 2
Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of Age
Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity).Irritability: mild (easily consolable), moderate (requiring increased attention), severe(Inconsolable; crying cannot be comforted).Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 1: Day 1 to Day 7 after Dose 3
Phase 1: Percentage of Participants Reporting Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 1: From Dose 1 to 1 Month after Dose 2
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method.
Time frame: Phase 1: From Dose 3 to 1 Month after Dose 3
Phase 1: Percentage of Participants Reporting Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 2: >=5 to <12 Years of Age
A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.
Time frame: Phase 1: From Dose 1 to 6 Months after Dose 2
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic Exact 2-sided 95% CI based on the Clopper and Pearson method.
Time frame: Phase 1: From Dose 3 to 6 Months after Dose 3
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 1: From Dose 1 to 1 Month after Dose 2
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=2 to <5 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI based on the Clopper and Pearson method. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 1: From Dose 3 to 1 Month after Dose 3
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.
Time frame: Phase 1: From Dose 1 to 6 Months after Dose 2
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=2 to <5 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.
Time frame: Phase 1: From Dose 3 to 6 Months after Dose 3
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=6 Months to <2 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 1: From Dose 1 to 1 Month after Dose 2
Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=6 Months to <2 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method.Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 1: From Dose 3 to 1 Month after Dose 3
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=6 Months to <2 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.Exact 2-sided 95% CI based on the Clopper and Pearson method.
Time frame: Phase 1: From Dose 1 to 6 Months after Dose 2
Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.
Time frame: Phase 1: From Dose 3 to 6 Months after Dose 3
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=5 to <12 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm),moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1:Troponin Group: >=5 to <12 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=5 to <12 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 2/3: From Dose 1 to 1 Month after Dose 2
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=12 to <16 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 2/3: From Dose 1 to 1 Month after Dose 2
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group: >=5 to <12 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 2/3: From Dose 3 to 1 Month after Dose 3
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group:>=12 to <16 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 3 to 1 month from dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 2/3: From Dose 3 to 1 Month after Dose 3
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : Troponin Group: >=5 to <12 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Phase 2/3: From Dose 1 to 6 Months after Dose 2
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Troponin Group: >=12 to <16 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Phase 2/3: From Dose 1 to 6 Months after Dose 2
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: Troponin Group: >=5 to <12 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Phase 2/3: From Dose 3 to 6 Months after Dose 3
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3 : Troponin Group:>=12 to <16 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Phase 2/3: From Dose 3 to 6 Months after Dose 3
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity),severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(\>=0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm),severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe(prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 deg C; categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C,\>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=5 to <12 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 deg C; categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C,\>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis\[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity),severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 deg C; categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C,\>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of Age
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate(hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2
Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of Age
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of Age
Systemic events recorded in an e-diary \& at unscheduled clinical assessments up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 deg C; categorised as \>=38.0 to 38.4 deg C,\>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating),moderate (decreased oral intake),severe(refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 1
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of Age
Systemic events recorded in an e-diary \& at unscheduled clinical assessments up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 deg C; categorised as \>=38.0 to 38.4 deg C,\>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 2
Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of Age
Systemic events recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 deg C; categorised as \>=38.0 to 38.4 deg C,\>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe(disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Phase 2/3: From Day 1 to Day 7 after Dose 3
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 2/3: From Dose 1 to 1 Month after Dose 2
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 2/3: From Dose 3 to 1 Month after Dose 3
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=5 to <12 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Phase 2/3: From Dose 1 to 6 Months after Dose 2
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Phase 2/3: From Dose 3 to 6 Months after Dose 3
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month from dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 2/3: From Dose 1 to 1 Month after Dose 2
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3:>=2 to <5 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 2/3: From Dose 3 to 1 Month after Dose 3
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Phase 2/3: From Dose 1 to 6 Months after Dose 2
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3:>=2 to <5 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Phase 2/3: From Dose 3 to 6 Months after Dose 3
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2 : >=6 Months to <2 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 2/3: From Dose 1 to 1 Month after Dose 2
Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3 : >=6 Months to <2 Years of Age
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Phase 2/3: From Dose 3 to 1 Month after Dose 3
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=6 Months to <2 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Phase 2/3: From Dose 1 to 6 Months after Dose 2
Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Phase 2/3: From Dose 3 to 6 Months after Dose 3
Phase2/3:Geometric Mean Ratio(GMR)Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants>=5 to<12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort:1 Month After Dose 2:Participants Without Evidence of Infection
GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of the titers and the corresponding CIs (based on student t distribution). GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants of the age 16 to 25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section and GMR is reported under statistical analysis.
Time frame: C4591007 (>=5 to <12 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=5 to <12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection
Seroresponse is defined as achieving a \>=4 fold rise from baseline (before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
Time frame: C4591007 (>=5 to <12 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection
GMRs \& corresponding 2-sided CIs were calculated by exponentiating mean difference of logarithm of titers \& corresponding CIs(based on student t distribution).GMTs \& 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs(based on the Student t distribution).Assay results below LLOQ were set to 0.5\*LLOQ.Results include those from comparator group of C4591001(NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\& had no medical history of COVID-19 were also included.GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.EIP included all eligible randomized participants who received study intervention to which they were randomized,had a valid\&determinate immunogenicity result within 28-42 days after study vaccination,had no other important protocol deviations as determined by clinician.
Time frame: C4591007 (>=2 to <5 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection
Seroresponse is defined as achieving a \>=4-fold rise from baseline (before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
Time frame: C4591007 (>=2 to <5 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection
GMRs \& corresponding 2-sided CIs were calculated by exponentiating mean difference of logarithm of titers \& corresponding CIs(based on student t distribution).GMTs \& 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs(based on the Student t distribution).Assay results below LLOQ were set to 0.5\*LLOQ.Results include those from comparator group of C4591001(NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\& had no medical history of COVID-19 were also included.GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.EIP included all eligible randomized participants who received study intervention to which they were randomized,had a valid\&determinate immunogenicity result within 28-42 days after study vaccination,had no other important protocol deviations as determined by clinician.
Time frame: C4591007 (>=6 Months to <2 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort : 1 Month After Dose 2: Participants Without Evidence of Infection
Seroresponse is defined as achieving a \>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
Time frame: C4591007 (>=6 Months to <2 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Phase 2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 3 in Participants Aged>=2 to<5Years Compared With Study C4591001 Phase2/3 16 to 25 Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection
GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of logarithm of the titers and the corresponding CIs(based on student t distribution).GMTs \& 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Results include those from comparator group of C4591001 (NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection \& had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.
Time frame: C4591007 (>=2 to <5 years):1 Month after Dose 2 and C4591001 Historical cohort (16-25 years):1 Month after Dose 2
Phase 2/3:Difference in Percentage of Participants With Seroresponse in 2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years of Age Historical Cohort: Participants Without Evidence of Infection
Seroresponse is defined as achieving a \>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse.Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
Time frame: C4591007 (>=2 to <5 years): 1 Month after Dose 3 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2
Phase2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose3 in Participants Aged 6Month to 2Year Compared With Study C4591001 Phase2/3 16 to 25Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection
GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of titers and the corresponding CIs (based on student t distribution). GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Results include those from comparator group of C4591001 (NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\& had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.
Time frame: C4591007 (>=6 months to <2 years):1 Month after Dose 3 and C4591001 Historical cohort (16-25 years):1 Month after Dose 2
Phase 2/3:Difference in Percentage of Participants With Seroresponse in 6 Months to <2 Years (1 Month After Dose 3) Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort (1 Month After Dose 2): Participants Without Evidence of Infection
Seroresponse is defined as achieving a \>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
Time frame: C4591007 (>=6 Months to <2 years):1 Month after Dose 3 and C4591001 Historical cohort (16-25 years):1 month after Dose 2
Phase 1: Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=6 Months to <2 Years of Age: Participants Without Evidence of Infection
GMT of SARS-CoV-2 neutralizing titer after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.
Time frame: Phase 1: 7 days post Dose 2
Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=2 to <5 Years of Age: Participants Without Evidence of Infection
GMT of SARS-CoV-2 neutralizing titers after the study vaccination was reported in this outcome measure. GMT and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution).Assay results below the LLOQ were set to 0.5\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.
Time frame: Phase 1: 7 days post Dose 2
Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=5 to <12 Years of Age: Participants Without Evidence of Infection
GMT of SARS-CoV-2 neutralizing titer after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.
Time frame: Phase 1: 7 days post Dose 2
Phase 2/3: Geometric Mean Titer - Neutralizing Titer (NT50) : 5 to <12 Years of Age: Before Dose 1 and 1 Month After Dose 2:Participants Without Evidence of Infection
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
Time frame: Phase 2/3: Before Dose 1 and 1 Month after Dose 2
Phase 2/3: Geometric Mean Titer - NT50: 5 to <12 Years of Age: Pre-Dose 3 and 1 Month After Dose 3:Participants Without Evidence of Infection
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 \*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population (EIP) included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
Time frame: Phase 2/3: From Dose 3 set: Pre-Dose 3 and 1 Month after Dose 3
Phase 2/3: Geometric Mean Titer - NT50:2 to <5 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 \*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19.
Time frame: Phase 2/3: From Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3
Phase 2/3: Geometric Mean Titer- NT50:6 Months to <2 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19.
Time frame: Phase 2/3: From Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3
Phase 2/3: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Dose 1 to 1 Month After Dose 2: >=5 to 12 Years of Age: Participants Without Evidence of Infection
GMFR of SARS-CoV-2 neutralizing titers from dose 1 to 1 month after dose 2 were reported in this outcome measure. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Assay results below the LLOQ were set to 0.5\* LLOQ in the analysis.
Time frame: Phase 2/3: From Dose 1 to 1 Month after Dose 2
Phase 2/3:GMFR of SARS-CoV-2 Neutralizing Titers From Dose 3 to 1 Month After Dose 3: >=5 to 12 Years of Age: Participants Without Evidence of Infection
GMFR of SARS-CoV-2 neutralizing titers from before Dose 3 to 1 month after Dose were reported in this outcome measure. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomized participants who received the study interventions to which they were randomized, had a valid and determined immunogenicity result within 28-42 days after Dose 3, and had no other important protocol deviations as determined by the clinicians.
Time frame: Phase 2/3: From Dose 3 to 1 Month after Dose 3
Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Pre-Dose 3 and 1 Month After Dose 3: >=2 to 5 Years of Age: Participants Without Evidence of Infection
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs(based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 infection.Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.
Time frame: Phase 2/3: From before dose 1 to Pre-Dose 3, 1 Month After Dose 3
Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Pre-Dose 3 and 1 Month After Dose 3: >=6 Months to 2 Years of Age: Participants Without Evidence of Infection
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection prior to the 1-month post-Dose 2.
Time frame: Phase 2/3: From before dose 1 to Pre-Dose 3, 1 Month After Dose 3
Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=5 to <12 Years of Age
COVID-19 incidence from 7 days after dose 2 to prior to dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviations as determined by clinician on or before 7 days after Dose 2.
Time frame: Phase 2/3: From 7 days after Dose 2 to prior to Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.591; Placebo - 0.292)
Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=5 to <12 Years of Age
COVID-19 incidence from 7 days after dose 2 to prior to dose 3 with or without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviation as determined by clinician on or before 7 days after Dose 2.
Time frame: Phase 2/3: From 7 Days After Dose 2 to prior to Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.653; Placebo - 0.326)
Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=6 Months to <5 Years of Age
COVID-19 incidence from 7 days after dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by clinician on or before 7 days after Dose 3.
Time frame: Phase 2/3: From 7 Days After Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.124; Placebo - 0.054)
Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=6 Months to <5 Years of Age
COVID-19 incidence from 7 days after dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by the clinician on or before 7 days after Dose 3.
Time frame: Phase 2/3: From 7 Days After Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.149; Placebo - 0.067)
The study consisted of 2 parts, Phase 1 and Phase 2/3.
| Milestone | Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age | Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age | Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age | Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3:Troponin Group:Placebo:5 to <12 Years of Age | Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 16 | 16 | 32 | 16 | 16 | 4 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Vaccination 1 | 16 | 16 | 32 | 16 | 16 | 4 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Vaccination 2 | 16 | 16 | 32 | 16 | 16 | 4 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Vaccination 3 | 15 | 13 | 27 | 16 | 8 | 4 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Safety population | 16 | 16 | 32 | 16 | 16 | 4 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 8 | 7 | 14 | 2 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 8 | 9 | 18 | 14 | 13 | 2 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 2 | 8 | 5 | 9 | 1 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 6 | 3 | 4 | 8 | 2 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian/participants | 1 | 3 | 4 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age | Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age | Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age | Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3:Troponin Group:Placebo:5 to <12 Years of Age | Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1458 | 718 | 2368 | 1173 | 3109 | 1538 | 518 | 260 | 506 |
| Vaccination 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1458 | 718 | 2368 | 1173 | 3109 | 1538 | 518 | 260 | 506 |
| Vaccination 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1445 | 672 | 2343 | 1073 | 3101 | 1532 | 514 | 110 | 496 |
| Vaccination 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1324 | 237 | 2093 | 405 | 2555 | 0 | 429 | 0 | 452 |
| Safety population | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1458 | 718 | 2368 | 1173 | 3109 | 1538 | 518 | 260 | 487 |
| First dose of bnt162b2 in open label period after unblinding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 581 | 0 | 787 | 0 | 1262 | 0 | 243 | 0 |
| Second dose of bnt162b2 in open label period after unblinding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 569 | 0 | 772 | 0 | 1254 | 0 | 239 | 0 |
| Third dose of bnt162b2 in open label period after unblinding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 534 | 0 | 694 | 0 | 1048 | 0 | 211 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 712 | 261 | 1214 | 406 | 1605 | 635 | 395 | 188 | 443 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 746 | 457 | 1154 | 767 | 1504 | 903 | 123 | 72 | 63 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 16 | 148 | 82 | 474 | 272 | 31 | 20 | 6 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 465 | 221 | 464 | 171 | 86 | 47 | 11 | 4 | 0 |
| Withdrew: Withdrawal by parent/guardian/participants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 199 | 196 | 428 | 458 | 816 | 543 | 66 | 37 | 40 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53 | 23 | 109 | 55 | 126 | 41 | 14 | 10 | 15 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Refused further study procedures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
Local reactions were collected in electronic diary (e-diary) or during unscheduled clinical assessments from Day 1 to 7 after Dose 1. Redness and swelling were measured and recorded in measuring device unit (mdu) where, 1 mdu = 0.5 centimeter (cm) and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 Emergency room (ER) visit or hospitalization). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% confidence interval was based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age |
|---|---|---|---|---|
| Redness: Any | 12.5 (1.6 to 38.3) | 0 (0.0 to 20.6) | 100.0 (39.8 to 100.0) | 16.7 (2.1 to 48.4) |
| Redness: Mild | 6.3 (0.2 to 30.2) | 0 (0.0 to 20.6) | 25.0 (0.6 to 80.6) | 0 (0.0 to 26.5) |
| Redness: Moderate | 6.3 (0.2 to 30.2) | 0 (0.0 to 20.6) | 75.0 (19.4 to 99.4) | 16.7 (2.1 to 48.4) |
| Redness: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Redness: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Swelling: Any | 18.8 (4.0 to 45.6) | 6.3 (0.2 to 30.2) | 50.0 (6.8 to 93.2) | 8.3 (0.2 to 38.5) |
| Swelling: Mild | 6.3 (0.2 to 30.2) | 0 (0.0 to 20.6) | 25.0 (0.6 to 80.6) | 0 (0.0 to 26.5) |
| Swelling: Moderate | 12.5 (1.6 to 38.3) | 6.3 (0.2 to 30.2) | 25.0 (0.6 to 80.6) | 8.3 (0.2 to 38.5) |
| Swelling: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Swelling: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Pain at the injection site: Any | 87.5 (61.7 to 98.4) | 93.8 (69.8 to 99.8) | 100.0 (39.8 to 100.0) | 83.3 (51.6 to 97.9) |
| Pain at the injection site: Mild | 68.8 (41.3 to 89.0) | 56.3 (29.9 to 80.2) | 50.0 (6.8 to 93.2) | 50.0 (21.1 to 78.9) |
| Pain at the injection site: Moderate | 18.8 (4.0 to 45.6) | 37.5 (15.2 to 64.6) | 50.0 (6.8 to 93.2) | 33.3 (9.9 to 65.1) |
| Pain at the injection site: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age |
|---|---|---|---|---|
| Redness: Any | 37.5 (15.2 to 64.6) | 18.8 (4.0 to 45.6) | 75.0 (19.4 to 99.4) | 16.7 (2.1 to 48.4) |
| Redness: Mild | 25.0 (7.3 to 52.4) | 6.3 (0.2 to 30.2) | 25.0 (0.6 to 80.6) | 8.3 (0.2 to 38.5) |
| Redness: Moderate | 12.5 (1.6 to 38.3) | 12.5 (1.6 to 38.3) | 25.0 (0.6 to 80.6) | 8.3 (0.2 to 38.5) |
| Redness: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 25.0 (0.6 to 80.6) | 0 (0.0 to 26.5) |
| Redness: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Swelling: Any | 31.3 (11.0 to 58.7) | 18.8 (4.0 to 45.6) | 50.0 (6.8 to 93.2) | 0 (0.0 to 26.5) |
| Swelling: Mild | 12.5 (1.6 to 38.3) | 0 (0.0 to 20.6) | 50.0 (6.8 to 93.2) | 0 (0.0 to 26.5) |
| Swelling: Moderate | 18.8 (4.0 to 45.6) | 18.8 (4.0 to 45.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Swelling: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Swelling: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Pain at the injection site: Any | 87.5 (61.7 to 98.4) | 75.0 (47.6 to 92.7) | 100.0 (39.8 to 100.0) | 91.7 (61.5 to 99.8) |
| Pain at the injection site: Mild | 75.0 (47.6 to 92.7) | 50.0 (24.7 to 75.3) | 50.0 (6.8 to 93.2) | 83.3 (51.6 to 97.9) |
| Pain at the injection site: Moderate | 12.5 (1.6 to 38.3) | 25.0 (7.3 to 52.4) | 50.0 (6.8 to 93.2) | 8.3 (0.2 to 38.5) |
| Pain at the injection site: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 1: 5 to <12 Years BNT162b2 10 mcg |
|---|---|
| Redness: Any | 28.9 (15.4 to 45.9) |
| Redness: Mild | 21.1 (9.6 to 37.3) |
| Redness: Moderate | 7.9 (1.7 to 21.4) |
| Redness: Severe | 0 (0.0 to 9.3) |
| Redness: Grade 4 | 0 (0.0 to 9.3) |
| Swelling: Any | 13.2 (4.4 to 28.1) |
| Swelling: Mild | 10.5 (2.9 to 24.8) |
| Swelling: Moderate | 2.6 (0.1 to 13.8) |
| Swelling: Severe | 0 (0.0 to 9.3) |
| Swelling: Grade 4 | 0 (0.0 to 9.3) |
| Pain at the injection site: Any | 86.8 (71.9 to 95.6) |
| Pain at the injection site: Mild | 68.4 (51.3 to 82.5) |
| Pain at the injection site: Moderate | 18.4 (7.7 to 34.3) |
| Pain at the injection site: Severe | 0 (0.0 to 9.3) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 9.3) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 degree Celsius (deg C); categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age |
|---|---|---|---|---|
| Fever: >=38.0 deg C | 6.3 (0.2 to 30.2) | 6.3 (0.2 to 30.2) | 0 (0.0 to 60.2) | 33.3 (9.9 to 65.1) |
| Fever:38.0 to 38.4 deg C | 6.3 (0.2 to 30.2) | 6.3 (0.2 to 30.2) | 0 (0.0 to 60.2) | 16.7 (2.1 to 48.4) |
| Fever: >38.4 to 38.9 deg C | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 16.7 (2.1 to 48.4) |
| Fever: >38.9 to 40.0 deg C | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Fever: >40.0 deg C | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Fatigue: Any | 50.0 (24.7 to 75.3) | 68.8 (41.3 to 89.0) | 100.0 (39.8 to 100.0) | 50.0 (21.1 to 78.9) |
| Fatigue: Mild | 37.5 (15.2 to 64.6) | 31.3 (11.0 to 58.7) | 25.0 (0.6 to 80.6) | 16.7 (2.1 to 48.4) |
| Fatigue: Moderate | 12.5 (1.6 to 38.3) | 37.5 (15.2 to 64.6) | 75.0 (19.4 to 99.4) | 33.3 (9.9 to 65.1) |
| Fatigue: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Fatigue: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Headache: Any | 25.0 (7.3 to 52.4) | 31.3 (11.0 to 58.7) | 75.0 (19.4 to 99.4) | 33.3 (9.9 to 65.1) |
| Headache: Mild | 18.8 (4.0 to 45.6) | 31.3 (11.0 to 58.7) | 50.0 (6.8 to 93.2) | 25.0 (5.5 to 57.2) |
| Headache: Moderate | 6.3 (0.2 to 30.2) | 0 (0.0 to 20.6) | 25.0 (0.6 to 80.6) | 8.3 (0.2 to 38.5) |
| Headache: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Headache: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Chills: Any | 0 (0.0 to 20.6) | 25.0 (7.3 to 52.4) | 50.0 (6.8 to 93.2) | 16.7 (2.1 to 48.4) |
| Chills: Mild | 0 (0.0 to 20.6) | 18.8 (4.0 to 45.6) | 0 (0.0 to 60.2) | 8.3 (0.2 to 38.5) |
| Chills: Moderate | 0 (0.0 to 20.6) | 6.3 (0.2 to 30.2) | 50.0 (6.8 to 93.2) | 8.3 (0.2 to 38.5) |
| Chills: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Chills: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Vomiting: Any | 0 (0.0 to 20.6) | 6.3 (0.2 to 30.2) | 0 (0.0 to 60.2) | 8.3 (0.2 to 38.5) |
| Vomiting: Mild | 0 (0.0 to 20.6) | 6.3 (0.2 to 30.2) | 0 (0.0 to 60.2) | 8.3 (0.2 to 38.5) |
| Vomiting: Moderate | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Vomiting: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Vomiting: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Diarrhea: Any | 6.3 (0.2 to 30.2) | 6.3 (0.2 to 30.2) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Diarrhea: Mild | 6.3 (0.2 to 30.2) | 6.3 (0.2 to 30.2) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Diarrhea: Moderate | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Diarrhea: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Diarrhea: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| New or worsened muscle pain: Any | 12.5 (1.6 to 38.3) | 25.0 (7.3 to 52.4) | 100.0 (39.8 to 100.0) | 0 (0.0 to 26.5) |
| New or worsened muscle pain: Mild | 6.3 (0.2 to 30.2) | 25.0 (7.3 to 52.4) | 25.0 (0.6 to 80.6) | 0 (0.0 to 26.5) |
| New or worsened muscle pain: Moderate | 6.3 (0.2 to 30.2) | 0 (0.0 to 20.6) | 75.0 (19.4 to 99.4) | 0 (0.0 to 26.5) |
| New or worsened muscle pain: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| New or worsened joint pain: Any | 6.3 (0.2 to 30.2) | 6.3 (0.2 to 30.2) | 25.0 (0.6 to 80.6) | 8.3 (0.2 to 38.5) |
| New or worsened joint pain: Mild | 6.3 (0.2 to 30.2) | 6.3 (0.2 to 30.2) | 0 (0.0 to 60.2) | 8.3 (0.2 to 38.5) |
| New or worsened joint pain: Moderate | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 25.0 (0.6 to 80.6) | 0 (0.0 to 26.5) |
| New or worsened joint pain: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age |
|---|---|---|---|---|
| Fever: >=38.0 deg C | 12.5 (1.6 to 38.3) | 18.8 (4.0 to 45.6) | 100.0 (39.8 to 100.0) | 0 (0.0 to 26.5) |
| Fever: 38.0 to 38.4 deg C | 0 (0.0 to 20.6) | 6.3 (0.2 to 30.2) | 75.0 (19.4 to 99.4) | 0 (0.0 to 26.5) |
| Fever: >38.4 to 38.9 deg C | 6.3 (0.2 to 30.2) | 6.3 (0.2 to 30.2) | 25.0 (0.6 to 80.6) | 0 (0.0 to 26.5) |
| Fever: >38.9 to 40.0 deg C | 6.3 (0.2 to 30.2) | 6.3 (0.2 to 30.2) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Fever: >40.0 deg C | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Fatigue: Any | 68.8 (41.3 to 89.0) | 62.5 (35.4 to 84.8) | 100.0 (39.8 to 100.0) | 75.0 (42.8 to 94.5) |
| Fatigue: Mild | 43.8 (19.8 to 70.1) | 25.0 (7.3 to 52.4) | 25.0 (0.6 to 80.6) | 58.3 (27.7 to 84.8) |
| Fatigue: Moderate | 25.0 (7.3 to 52.4) | 37.5 (15.2 to 64.6) | 75.0 (19.4 to 99.4) | 16.7 (2.1 to 48.4) |
| Fatigue: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Fatigue: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Headache: Any | 50.0 (24.7 to 75.3) | 56.3 (29.9 to 80.2) | 75.0 (19.4 to 99.4) | 33.3 (9.9 to 65.1) |
| Headache: Mild | 25.0 (7.3 to 52.4) | 25.0 (7.3 to 52.4) | 25.0 (0.6 to 80.6) | 25.0 (5.5 to 57.2) |
| Headache: Moderate | 25.0 (7.3 to 52.4) | 31.3 (11.0 to 58.7) | 50.0 (6.8 to 93.2) | 8.3 (0.2 to 38.5) |
| Headache: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Headache: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Chills: Any | 31.3 (11.0 to 58.7) | 43.8 (19.8 to 70.1) | 75.0 (19.4 to 99.4) | 33.3 (9.9 to 65.1) |
| Chills: Mild | 25.0 (7.3 to 52.4) | 25.0 (7.3 to 52.4) | 75.0 (19.4 to 99.4) | 33.3 (9.9 to 65.1) |
| Chills: Moderate | 6.3 (0.2 to 30.2) | 18.8 (4.0 to 45.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Chills: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Chills: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Vomiting: Any | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 25.0 (0.6 to 80.6) | 8.3 (0.2 to 38.5) |
| Vomiting: Mild | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 25.0 (0.6 to 80.6) | 8.3 (0.2 to 38.5) |
| Vomiting: Moderate | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Vomiting: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Vomiting: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Diarrhea: Any | 6.3 (0.2 to 30.2) | 0 (0.0 to 20.6) | 50.0 (6.8 to 93.2) | 0 (0.0 to 26.5) |
| Diarrhea: Mild | 6.3 (0.2 to 30.2) | 0 (0.0 to 20.6) | 50.0 (6.8 to 93.2) | 0 (0.0 to 26.5) |
| Diarrhea: Moderate | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Diarrhea: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| Diarrhea: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| New or worsened muscle pain: Any | 0 (0.0 to 20.6) | 18.8 (4.0 to 45.6) | 50.0 (6.8 to 93.2) | 8.3 (0.2 to 38.5) |
| New or worsened muscle pain: Mild | 0 (0.0 to 20.6) | 18.8 (4.0 to 45.6) | 0 (0.0 to 60.2) | 8.3 (0.2 to 38.5) |
| New or worsened muscle pain: Moderate | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 50.0 (6.8 to 93.2) | 0 (0.0 to 26.5) |
| New or worsened muscle pain: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| New or worsened joint pain: Any | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 25.0 (0.6 to 80.6) | 0 (0.0 to 26.5) |
| New or worsened joint pain: Mild | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| New or worsened joint pain: Moderate | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 25.0 (0.6 to 80.6) | 0 (0.0 to 26.5) |
| New or worsened joint pain: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 20.6) | 0 (0.0 to 60.2) | 0 (0.0 to 26.5) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 1: 5 to <12 Years BNT162b2 10 mcg |
|---|---|
| Fever:>=38.0 deg C | 2.6 (0.1 to 13.8) |
| Fever:38.0 to 38.4 deg C | 0 (0.0 to 9.3) |
| Fever: >38.4 to 38.9 deg C | 0 (0.0 to 9.3) |
| Fever: >38.9 to 40.0 deg C | 2.6 (0.1 to 13.8) |
| Fever: >40.0 deg C | 0 (0.0 to 9.3) |
| Fatigue: Any | 39.5 (24.0 to 56.6) |
| Fatigue: Mild | 21.1 (9.6 to 37.3) |
| Fatigue: Moderate | 15.8 (6.0 to 31.3) |
| Fatigue: Severe | 2.6 (0.1 to 13.8) |
| Fatigue: Grade 4 | 0 (0.0 to 9.3) |
| Headache: Any | 34.2 (19.6 to 51.4) |
| Headache: Mild | 21.1 (9.6 to 37.3) |
| Headache: Moderate | 10.5 (2.9 to 24.8) |
| Headache: Severe | 2.6 (0.1 to 13.8) |
| Headache: Grade 4 | 0 (0.0 to 9.3) |
| Chills: Any | 15.8 (6.0 to 31.3) |
| Chills: Mild | 13.2 (4.4 to 28.1) |
| Chills: Moderate | 2.6 (0.1 to 13.8) |
| Chills: Severe | 0 (0.0 to 9.3) |
| Chills: Grade 4 | 0 (0.0 to 9.3) |
| Vomiting: Any | 2.6 (0.1 to 13.8) |
| Vomiting: Mild | 2.6 (0.1 to 13.8) |
| Vomiting: Moderate | 0 (0.0 to 9.3) |
| Vomiting: Severe | 0 (0.0 to 9.3) |
| Vomiting: Grade 4 | 0 (0.0 to 9.3) |
| Diarrhea: Any | 0 (0.0 to 9.3) |
| Diarrhea: Mild | 0 (0.0 to 9.3) |
| Diarrhea: Moderate | 0 (0.0 to 9.3) |
| Diarrhea: Severe | 0 (0.0 to 9.3) |
| Diarrhea: Grade 4 | 0 (0.0 to 9.3) |
| New or worsened muscle pain: Any | 7.9 (1.7 to 21.4) |
| New or worsened muscle pain: Mild | 2.6 (0.1 to 13.8) |
| New or worsened muscle pain: Moderate | 5.3 (0.6 to 17.7) |
| New or worsened muscle pain: Severe | 0 (0.0 to 9.3) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 9.3) |
| New or worsened joint pain: Any | 2.6 (0.1 to 13.8) |
| New or worsened joint pain: Mild | 0 (0.0 to 9.3) |
| New or worsened joint pain: Moderate | 2.6 (0.1 to 13.8) |
| New or worsened joint pain: Severe | 0 (0.0 to 9.3) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 9.3) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age |
|---|---|---|
| Redness: Any | 0 (0.0 to 20.6) | 28.1 (13.7 to 46.7) |
| Redness: Mild | 0 (0.0 to 20.6) | 25.0 (11.5 to 43.4) |
| Redness: Moderate | 0 (0.0 to 20.6) | 3.1 (0.1 to 16.2) |
| Redness: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Redness: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Swelling: Any | 0 (0.0 to 20.6) | 9.4 (2.0 to 25.0) |
| Swelling: Mild | 0 (0.0 to 20.6) | 6.3 (0.8 to 20.8) |
| Swelling: Moderate | 0 (0.0 to 20.6) | 3.1 (0.1 to 16.2) |
| Swelling: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Swelling: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Pain at the injection site: Any | 31.3 (11.0 to 58.7) | 62.5 (43.7 to 78.9) |
| Pain at the injection site: Mild | 25.0 (7.3 to 52.4) | 56.3 (37.7 to 73.6) |
| Pain at the injection site: Moderate | 6.3 (0.2 to 30.2) | 6.3 (0.8 to 20.8) |
| Pain at the injection site: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age |
|---|---|---|
| Redness: Any | 0 (0.0 to 20.6) | 15.6 (5.3 to 32.8) |
| Redness: Mild | 0 (0.0 to 20.6) | 15.6 (5.3 to 32.8) |
| Redness: Moderate | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Redness: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Redness: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Swelling: Any | 0 (0.0 to 20.6) | 3.1 (0.1 to 16.2) |
| Swelling: Mild | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Swelling: Moderate | 0 (0.0 to 20.6) | 3.1 (0.1 to 16.2) |
| Swelling: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Swelling: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Pain at the injection site: Any | 37.5 (15.2 to 64.6) | 53.1 (34.7 to 70.9) |
| Pain at the injection site: Mild | 37.5 (15.2 to 64.6) | 43.8 (26.4 to 62.3) |
| Pain at the injection site: Moderate | 0 (0.0 to 20.6) | 9.4 (2.0 to 25.0) |
| Pain at the injection site: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg) | Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg) |
|---|---|---|
| Redness: Any | 3.8 (0.1 to 19.6) | 15.4 (1.9 to 45.4) |
| Redness: Mild | 3.8 (0.1 to 19.6) | 15.4 (1.9 to 45.4) |
| Redness: Moderate | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Redness: Severe | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Redness: Grade 4 | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Swelling: Any | 0 (0.0 to 13.2) | 7.7 (0.2 to 36.0) |
| Swelling: Mild | 0 (0.0 to 13.2) | 7.7 (0.2 to 36.0) |
| Swelling: Moderate | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Swelling: Severe | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Swelling: Grade 4 | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Pain at the injection site: Any | 34.6 (17.2 to 55.7) | 84.6 (54.6 to 98.1) |
| Pain at the injection site: Mild | 34.6 (17.2 to 55.7) | 38.5 (13.9 to 68.4) |
| Pain at the injection site: Moderate | 0 (0.0 to 13.2) | 38.5 (13.9 to 68.4) |
| Pain at the injection site: Severe | 0 (0.0 to 13.2) | 7.7 (0.2 to 36.0) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age |
|---|---|---|
| Fever: >=38.0 deg C | 0 (0.0 to 20.6) | 18.8 (7.2 to 36.4) |
| Fever: 38.0 to 38.4 deg C | 0 (0.0 to 20.6) | 6.3 (0.8 to 20.8) |
| Fever: >38.4 to 38.9 deg C | 0 (0.0 to 20.6) | 6.3 (0.8 to 20.8) |
| Fever: >38.9 to 40.0 deg C | 0 (0.0 to 20.6) | 6.3 (0.8 to 20.8) |
| Fever: >40.0 deg C | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Fatigue: Any | 25.0 (7.3 to 52.4) | 46.9 (29.1 to 65.3) |
| Fatigue: Mild | 18.8 (4.0 to 45.6) | 34.4 (18.6 to 53.2) |
| Fatigue: Moderate | 6.3 (0.2 to 30.2) | 12.5 (3.5 to 29.0) |
| Fatigue: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Fatigue: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Headache: Any | 12.5 (1.6 to 38.3) | 9.4 (2.0 to 25.0) |
| Headache: Mild | 6.3 (0.2 to 30.2) | 6.3 (0.8 to 20.8) |
| Headache: Moderate | 6.3 (0.2 to 30.2) | 3.1 (0.1 to 16.2) |
| Headache: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Headache: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Chills: Any | 6.3 (0.2 to 30.2) | 6.3 (0.8 to 20.8) |
| Chills: Mild | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Chills: Moderate | 6.3 (0.2 to 30.2) | 6.3 (0.8 to 20.8) |
| Chills: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Chills: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Vomiting: Any | 0 (0.0 to 20.6) | 3.1 (0.1 to 16.2) |
| Vomiting: Mild | 0 (0.0 to 20.6) | 3.1 (0.1 to 16.2) |
| Vomiting: Moderate | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Vomiting: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Vomiting: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Diarrhea: Any | 6.3 (0.2 to 30.2) | 6.3 (0.8 to 20.8) |
| Diarrhea: Mild | 6.3 (0.2 to 30.2) | 6.3 (0.8 to 20.8) |
| Diarrhea: Moderate | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Diarrhea: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Diarrhea: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| New or worsened muscle pain: Any | 0 (0.0 to 20.6) | 6.3 (0.8 to 20.8) |
| New or worsened muscle pain: Mild | 0 (0.0 to 20.6) | 3.1 (0.1 to 16.2) |
| New or worsened muscle pain: Moderate | 0 (0.0 to 20.6) | 3.1 (0.1 to 16.2) |
| New or worsened muscle pain: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| New or worsened joint pain: Any | 6.3 (0.2 to 30.2) | 0 (0.0 to 10.9) |
| New or worsened joint pain: Mild | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| New or worsened joint pain: Moderate | 6.3 (0.2 to 30.2) | 0 (0.0 to 10.9) |
| New or worsened joint pain: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age |
|---|---|---|
| Fever: >=38.0 deg C | 6.3 (0.2 to 30.2) | 18.8 (7.2 to 36.4) |
| Fever: 38.0 to 38.4 deg C | 0 (0.0 to 20.6) | 9.4 (2.0 to 25.0) |
| Fever: >38.4 to 38.9 deg C | 6.3 (0.2 to 30.2) | 3.1 (0.1 to 16.2) |
| Fever: >38.9 to 40.0 deg C | 0 (0.0 to 20.6) | 6.3 (0.8 to 20.8) |
| Fever: >40.0 deg C | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Fatigue: Any | 25.0 (7.3 to 52.4) | 59.4 (40.6 to 76.3) |
| Fatigue: Mild | 12.5 (1.6 to 38.3) | 31.3 (16.1 to 50.0) |
| Fatigue: Moderate | 12.5 (1.6 to 38.3) | 28.1 (13.7 to 46.7) |
| Fatigue: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Fatigue: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Headache: Any | 12.5 (1.6 to 38.3) | 15.6 (5.3 to 32.8) |
| Headache: Mild | 6.3 (0.2 to 30.2) | 9.4 (2.0 to 25.0) |
| Headache: Moderate | 6.3 (0.2 to 30.2) | 6.3 (0.8 to 20.8) |
| Headache: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Headache: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Chills: Any | 6.3 (0.2 to 30.2) | 6.3 (0.8 to 20.8) |
| Chills: Mild | 0 (0.0 to 20.6) | 6.3 (0.8 to 20.8) |
| Chills: Moderate | 6.3 (0.2 to 30.2) | 0 (0.0 to 10.9) |
| Chills: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Chills: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Vomiting: Any | 6.3 (0.2 to 30.2) | 6.3 (0.8 to 20.8) |
| Vomiting: Mild | 6.3 (0.2 to 30.2) | 3.1 (0.1 to 16.2) |
| Vomiting: Moderate | 0 (0.0 to 20.6) | 3.1 (0.1 to 16.2) |
| Vomiting: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Vomiting: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Diarrhea: Any | 6.3 (0.2 to 30.2) | 12.5 (3.5 to 29.0) |
| Diarrhea: Mild | 6.3 (0.2 to 30.2) | 12.5 (3.5 to 29.0) |
| Diarrhea: Moderate | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Diarrhea: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| Diarrhea: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| New or worsened muscle pain: Any | 0 (0.0 to 20.6) | 9.4 (2.0 to 25.0) |
| New or worsened muscle pain: Mild | 0 (0.0 to 20.6) | 6.3 (0.8 to 20.8) |
| New or worsened muscle pain: Moderate | 0 (0.0 to 20.6) | 3.1 (0.1 to 16.2) |
| New or worsened muscle pain: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| New or worsened joint pain: Any | 0 (0.0 to 20.6) | 3.1 (0.1 to 16.2) |
| New or worsened joint pain: Mild | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| New or worsened joint pain: Moderate | 0 (0.0 to 20.6) | 3.1 (0.1 to 16.2) |
| New or worsened joint pain: Severe | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg) | Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg) |
|---|---|---|
| Fever: >=38.0 deg C | 0 (0.0 to 13.2) | 15.4 (1.9 to 45.4) |
| Fever: 38.0 to 38.4 deg C | 0 (0.0 to 13.2) | 7.7 (0.2 to 36.0) |
| Fever: >38.4 to 38.9 deg C | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Fever: >38.9 to 40.0 deg C | 0 (0.0 to 13.2) | 7.7 (0.2 to 36.0) |
| Fever: >40.0 deg C | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Fatigue: Any | 30.8 (14.3 to 51.8) | 53.8 (25.1 to 80.8) |
| Fatigue: Mild | 19.2 (6.6 to 39.4) | 23.1 (5.0 to 53.8) |
| Fatigue: Moderate | 11.5 (2.4 to 30.2) | 30.8 (9.1 to 61.4) |
| Fatigue: Severe | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Fatigue: Grade 4 | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Headache: Any | 3.8 (0.1 to 19.6) | 23.1 (5.0 to 53.8) |
| Headache: Mild | 3.8 (0.1 to 19.6) | 15.4 (1.9 to 45.4) |
| Headache: Moderate | 0 (0.0 to 13.2) | 7.7 (0.2 to 36.0) |
| Headache: Severe | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Headache: Grade 4 | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Chills: Any | 0 (0.0 to 13.2) | 15.4 (1.9 to 45.4) |
| Chills: Mild | 0 (0.0 to 13.2) | 7.7 (0.2 to 36.0) |
| Chills: Moderate | 0 (0.0 to 13.2) | 7.7 (0.2 to 36.0) |
| Chills: Severe | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Chills: Grade 4 | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Vomiting: Any | 0 (0.0 to 13.2) | 23.1 (5.0 to 53.8) |
| Vomiting: Mild | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Vomiting: Moderate | 0 (0.0 to 13.2) | 23.1 (5.0 to 53.8) |
| Vomiting: Severe | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Vomiting: Grade 4 | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Diarrhea: Any | 3.8 (0.1 to 19.6) | 7.7 (0.2 to 36.0) |
| Diarrhea: Mild | 3.8 (0.1 to 19.6) | 7.7 (0.2 to 36.0) |
| Diarrhea: Moderate | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Diarrhea: Severe | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| Diarrhea: Grade 4 | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| New or worsened muscle pain: Any | 0 (0.0 to 13.2) | 15.4 (1.9 to 45.4) |
| New or worsened muscle pain: Mild | 0 (0.0 to 13.2) | 7.7 (0.2 to 36.0) |
| New or worsened muscle pain: Moderate | 0 (0.0 to 13.2) | 7.7 (0.2 to 36.0) |
| New or worsened muscle pain: Severe | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| New or worsened joint pain: Any | 0 (0.0 to 13.2) | 7.7 (0.2 to 36.0) |
| New or worsened joint pain: Mild | 0 (0.0 to 13.2) | 7.7 (0.2 to 36.0) |
| New or worsened joint pain: Moderate | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| New or worsened joint pain: Severe | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 13.2) | 0 (0.0 to 24.7) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age |
|---|---|
| Redness: Any | 18.8 (4.0 to 45.6) |
| Redness: Mild | 18.8 (4.0 to 45.6) |
| Redness: Moderate | 0 (0.0 to 20.6) |
| Redness: Severe | 0 (0.0 to 20.6) |
| Redness: Grade 4 | 0 (0.0 to 20.6) |
| Swelling: Any | 6.3 (0.2 to 30.2) |
| Swelling: Mild | 6.3 (0.2 to 30.2) |
| Swelling: Moderate | 0 (0.0 to 20.6) |
| Swelling: Severe | 0 (0.0 to 20.6) |
| Swelling: Grade 4 | 0 (0.0 to 20.6) |
| Tenderness at the injection site: Any | 0 (0.0 to 20.6) |
| Tenderness at the injection site: Mild | 0 (0.0 to 20.6) |
| Tenderness at the injection site: Moderate | 0 (0.0 to 20.6) |
| Tenderness at the injection site: Severe | 0 (0.0 to 20.6) |
| Tenderness at the injection site: Grade 4 | 0 (0.0 to 20.6) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age |
|---|---|
| Redness: Any | 0 (0.0 to 20.6) |
| Redness: Mild | 0 (0.0 to 20.6) |
| Redness: Moderate | 0 (0.0 to 20.6) |
| Redness: Severe | 0 (0.0 to 20.6) |
| Redness: Grade 4 | 0 (0.0 to 20.6) |
| Swelling: Any | 0 (0.0 to 20.6) |
| Swelling: Mild | 0 (0.0 to 20.6) |
| Swelling: Moderate | 0 (0.0 to 20.6) |
| Swelling: Severe | 0 (0.0 to 20.6) |
| Swelling: Grade 4 | 0 (0.0 to 20.6) |
| Tenderness at the injection site: Any | 6.3 (0.2 to 30.2) |
| Tenderness at the injection site: Mild | 6.3 (0.2 to 30.2) |
| Tenderness at the injection site: Moderate | 0 (0.0 to 20.6) |
| Tenderness at the injection site: Severe | 0 (0.0 to 20.6) |
| Tenderness at the injection site: Grade 4 | 0 (0.0 to 20.6) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization for severe tenderness at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age |
|---|---|
| Redness: Any | 13.3 (1.7 to 40.5) |
| Redness: Mild | 13.3 (1.7 to 40.5) |
| Redness: Moderate | 0 (0.0 to 21.8) |
| Redness: Severe | 0 (0.0 to 21.8) |
| Redness: Grade 4 | 0 (0.0 to 21.8) |
| Swelling: Any | 6.7 (0.2 to 31.9) |
| Swelling: Mild | 6.7 (0.2 to 31.9) |
| Swelling: Moderate | 0 (0.0 to 21.8) |
| Swelling: Severe | 0 (0.0 to 21.8) |
| Swelling: Grade 4 | 0 (0.0 to 21.8) |
| Tenderness at the injection site: Any | 26.7 (7.8 to 55.1) |
| Tenderness at the injection site: Mild | 26.7 (7.8 to 55.1) |
| Tenderness at the injection site: Moderate | 0 (0.0 to 21.8) |
| Tenderness at the injection site: Severe | 0 (0.0 to 21.8) |
| Tenderness at the injection site: Grade 4 | 0 (0.0 to 21.8) |
Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age |
|---|---|
| Fever: >=38.0 deg C | 6.3 (0.2 to 30.2) |
| Fever: 38.0 to 38.4 deg C | 6.3 (0.2 to 30.2) |
| Fever: >38.4 to 38.9 deg C | 0 (0.0 to 20.6) |
| Fever: >38.9 to 40.0 deg C | 0 (0.0 to 20.6) |
| Fever: >40.0 deg C | 0 (0.0 to 20.6) |
| Decreased appetite: Any | 6.3 (0.2 to 30.2) |
| Decreased appetite: Mild | 0 (0.0 to 20.6) |
| Decreased appetite: Moderate | 6.3 (0.2 to 30.2) |
| Decreased appetite: Severe | 0 (0.0 to 20.6) |
| Decreased appetite: Grade 4 | 0 (0.0 to 20.6) |
| Drowsiness: Any | 25.0 (7.3 to 52.4) |
| Drowsiness: Mild | 18.8 (4.0 to 45.6) |
| Drowsiness: Moderate | 6.3 (0.2 to 30.2) |
| Drowsiness: Severe | 0 (0.0 to 20.6) |
| Drowsiness: Grade 4 | 0 (0.0 to 20.6) |
| Irritability: Any | 43.8 (19.8 to 70.1) |
| Irritability: Mild | 18.8 (4.0 to 45.6) |
| Irritability: Moderate | 25.0 (7.3 to 52.4) |
| Irritability: Severe | 0 (0.0 to 20.6) |
| Irritability: Grade 4 | 0 (0.0 to 20.6) |
Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 2.Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake),severe (refusal to feed).Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted).Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age |
|---|---|
| Fever: >=38.0 deg C | 12.5 (1.6 to 38.3) |
| Fever: 38.0 to 38.4 deg C | 12.5 (1.6 to 38.3) |
| Fever: >38.4 to 38.9 deg C | 0 (0.0 to 20.6) |
| Fever: >38.9 to 40.0 deg C | 0 (0.0 to 20.6) |
| Fever: >40.0 deg C | 0 (0.0 to 20.6) |
| Decreased appetite: Any | 12.5 (1.6 to 38.3) |
| Decreased appetite: Mild | 12.5 (1.6 to 38.3) |
| Decreased appetite: Moderate | 0 (0.0 to 20.6) |
| Decreased appetite: Severe | 0 (0.0 to 20.6) |
| Decreased appetite: Grade 4 | 0 (0.0 to 20.6) |
| Drowsiness: Any | 6.3 (0.2 to 30.2) |
| Drowsiness: Mild | 6.3 (0.2 to 30.2) |
| Drowsiness: Moderate | 0 (0.0 to 20.6) |
| Drowsiness: Severe | 0 (0.0 to 20.6) |
| Drowsiness: Grade 4 | 0 (0.0 to 20.6) |
| Irritability: Any | 31.3 (11.0 to 58.7) |
| Irritability: Mild | 31.3 (11.0 to 58.7) |
| Irritability: Moderate | 0 (0.0 to 20.6) |
| Irritability: Severe | 0 (0.0 to 20.6) |
| Irritability: Grade 4 | 0 (0.0 to 20.6) |
Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity).Irritability: mild (easily consolable), moderate (requiring increased attention), severe(Inconsolable; crying cannot be comforted).Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age |
|---|---|
| Fever: >=38.0 deg C | 6.7 (0.2 to 31.9) |
| Fever: 38.0 to 38.4 deg C | 0 (0.0 to 21.8) |
| Fever: >38.4 to 38.9 deg C | 0 (0.0 to 21.8) |
| Fever: >38.9 to 40.0 deg C | 6.7 (0.2 to 31.9) |
| Fever: >40.0 deg C | 0 (0.0 to 21.8) |
| Decreased appetite: Any | 13.3 (1.7 to 40.5) |
| Decreased appetite: Mild | 6.7 (0.2 to 31.9) |
| Decreased appetite: Moderate | 6.7 (0.2 to 31.9) |
| Decreased appetite: Severe | 0 (0.0 to 21.8) |
| Decreased appetite: Grade 4 | 0 (0.0 to 21.8) |
| Drowsiness: Any | 6.7 (0.2 to 31.9) |
| Drowsiness: Mild | 0 (0.0 to 21.8) |
| Drowsiness: Moderate | 6.7 (0.2 to 31.9) |
| Drowsiness: Severe | 0 (0.0 to 21.8) |
| Drowsiness: Grade 4 | 0 (0.0 to 21.8) |
| Irritability: Any | 26.7 (7.8 to 55.1) |
| Irritability: Mild | 13.3 (1.7 to 40.5) |
| Irritability: Moderate | 13.3 (1.7 to 40.5) |
| Irritability: Severe | 0 (0.0 to 21.8) |
| Irritability: Grade 4 | 0 (0.0 to 21.8) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age |
|---|---|---|---|---|
| Phase 1: Percentage of Participants Reporting Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age | 43.8 (19.8 to 70.1) | 31.3 (11.0 to 58.7) | 50.0 (6.8 to 93.2) | 25.0 (5.5 to 57.2) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method.
| Percentage of participants | Phase 1: 5 to <12 Years BNT162b2 10 mcg |
|---|---|
| Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age | 15.8 (6.0 to 31.3) |
A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age | Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age |
|---|---|---|---|---|
| Phase 1: Percentage of Participants Reporting Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 2: >=5 to <12 Years of Age | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic Exact 2-sided 95% CI based on the Clopper and Pearson method.
| Percentage of participants | Phase 1: 5 to <12 Years BNT162b2 10 mcg |
|---|---|
| Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age | 0 (0 to 0) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age |
|---|---|---|
| Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age | 25.0 (7.3 to 52.4) | 37.5 (21.1 to 56.3) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI based on the Clopper and Pearson method. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg) | Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg) |
|---|---|---|
| Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=2 to <5 Years of Age | 11.1 (2.4 to 29.2) | 0 (0.0 to 24.7) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age |
|---|---|---|
| Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age | 0 (0.0 to 20.6) | 0 (0.0 to 10.9) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg) | Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg) |
|---|---|---|
| Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=2 to <5 Years of Age | 0 (0 to 12.8) | 0 (0 to 24.7) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age |
|---|---|
| Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=6 Months to <2 Years of Age | 12.5 (1.6 to 38.3) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method.Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age |
|---|---|
| Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=6 Months to <2 Years of Age | 6.7 (0.2 to 31.9) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.Exact 2-sided 95% CI based on the Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age |
|---|---|
| Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=6 Months to <2 Years of Age | 0 (0 to 20.6) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.
| Percentage of participants | Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age |
|---|---|
| Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age | 0 (0 to 21.8) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Redness: Any | 15.5 (12.5 to 19.0) | 6.2 (3.6 to 9.8) |
| Redness: Mild | 11.8 (9.2 to 15.0) | 5.4 (3.0 to 8.9) |
| Redness: Moderate | 3.7 (2.2 to 5.7) | 0.4 (0.0 to 2.1) |
| Redness: Severe | 0 (0.0 to 0.7) | 0.4 (0.0 to 2.1) |
| Redness: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| Swelling: Any | 10.9 (8.3 to 13.9) | 4.6 (2.4 to 7.9) |
| Swelling: Mild | 7.6 (5.4 to 10.2) | 2.7 (1.1 to 5.5) |
| Swelling: Moderate | 3.3 (1.9 to 5.2) | 1.9 (0.6 to 4.4) |
| Swelling: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| Swelling: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| Pain at the injection site: Any | 72.4 (68.3 to 76.2) | 28.1 (22.7 to 34.0) |
| Pain at the injection site: Mild | 57.7 (53.3 to 62.0) | 23.5 (18.4 to 29.1) |
| Pain at the injection site: Moderate | 14.8 (11.8 to 18.1) | 4.6 (2.4 to 7.9) |
| Pain at the injection site: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age |
|---|---|
| Redness: Any | 2.1 (1.0 to 3.8) |
| Redness: Mild | 1.5 (0.6 to 3.0) |
| Redness: Moderate | 0.6 (0.1 to 1.8) |
| Redness: Severe | 0 (0.0 to 0.8) |
| Redness: Grade 4 | 0 (0.0 to 0.8) |
| Swelling: Any | 4.4 (2.8 to 6.7) |
| Swelling: Mild | 2.7 (1.5 to 4.6) |
| Swelling: Moderate | 1.7 (0.7 to 3.3) |
| Swelling: Severe | 0 (0.0 to 0.8) |
| Swelling: Grade 4 | 0 (0.0 to 0.8) |
| Pain at the injection site: Any | 72.4 (68.2 to 76.4) |
| Pain at the injection site: Mild | 43.8 (39.3 to 48.4) |
| Pain at the injection site: Moderate | 28.2 (24.2 to 32.5) |
| Pain at the injection site: Severe | 0.4 (0.1 to 1.5) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.8) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Redness: Any | 16.7 (13.5 to 20.3) | 1.9 (0.2 to 6.6) |
| Redness: Mild | 9.9 (7.4 to 12.8) | 1.9 (0.2 to 6.6) |
| Redness: Moderate | 6.8 (4.8 to 9.4) | 0 (0.0 to 3.4) |
| Redness: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| Redness: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| Swelling: Any | 11.5 (8.8 to 14.6) | 4.7 (1.5 to 10.6) |
| Swelling: Mild | 6.8 (4.8 to 9.4) | 2.8 (0.6 to 8.0) |
| Swelling: Moderate | 4.6 (3.0 to 6.9) | 1.9 (0.2 to 6.6) |
| Swelling: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| Swelling: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| Pain at the injection site: Any | 66.8 (62.5 to 70.9) | 23.4 (15.7 to 32.5) |
| Pain at the injection site: Mild | 48.3 (43.8 to 52.8) | 19.6 (12.6 to 28.4) |
| Pain at the injection site: Moderate | 18.5 (15.2 to 22.2) | 3.7 (1.0 to 9.3) |
| Pain at the injection site: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm),moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age |
|---|---|
| Redness: Any | 0.9 (0.2 to 2.3) |
| Redness: Mild | 0.4 (0.1 to 1.6) |
| Redness: Moderate | 0.2 (0.0 to 1.2) |
| Redness: Severe | 0.2 (0.0 to 1.2) |
| Redness: Grade 4 | 0 (0.0 to 0.8) |
| Swelling: Any | 1.8 (0.8 to 3.5) |
| Swelling: Mild | 0.9 (0.2 to 2.3) |
| Swelling: Moderate | 0.9 (0.2 to 2.3) |
| Swelling: Severe | 0 (0.0 to 0.8) |
| Swelling: Grade 4 | 0 (0.0 to 0.8) |
| Pain at the injection site: Any | 57.8 (53.1 to 62.4) |
| Pain at the injection site: Mild | 36.6 (32.1 to 41.3) |
| Pain at the injection site: Moderate | 20.8 (17.1 to 24.8) |
| Pain at the injection site: Severe | 0.4 (0.1 to 1.6) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.8) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age |
|---|---|
| Redness: Any | 17.0 (13.4 to 21.1) |
| Redness: Mild | 11.2 (8.2 to 14.7) |
| Redness: Moderate | 5.8 (3.7 to 8.6) |
| Redness: Severe | 0 (0.0 to 0.9) |
| Redness: Grade 4 | 0 (0.0 to 0.9) |
| Swelling: Any | 12.7 (9.6 to 16.4) |
| Swelling: Mild | 9.4 (6.7 to 12.7) |
| Swelling: Moderate | 3.3 (1.8 to 5.6) |
| Swelling: Severe | 0 (0.0 to 0.9) |
| Swelling: Grade 4 | 0 (0.0 to 0.9) |
| Pain at the injection site: Any | 69.3 (64.5 to 73.8) |
| Pain at the injection site: Mild | 48.0 (42.9 to 53.0) |
| Pain at the injection site: Moderate | 20.8 (16.9 to 25.2) |
| Pain at the injection site: Severe | 0.5 (0.1 to 1.8) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.9) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate (\>5.0 to 10.0), severe \>10.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age |
|---|---|
| Redness: Any | 3.5 (1.9 to 5.7) |
| Redness: Mild | 3.0 (1.5 to 5.1) |
| Redness: Moderate | 0.5 (0.1 to 1.8) |
| Redness: Severe | 0 (0.0 to 0.9) |
| Redness: Grade 4 | 0 (0.0 to 0.9) |
| Swelling: Any | 3.0 (1.5 to 5.1) |
| Swelling: Mild | 2.0 (0.9 to 3.9) |
| Swelling: Moderate | 1.0 (0.3 to 2.5) |
| Swelling: Severe | 0 (0.0 to 0.9) |
| Swelling: Grade 4 | 0 (0.0 to 0.9) |
| Pain at the injection site: Any | 63.5 (58.6 to 68.2) |
| Pain at the injection site: Mild | 35.8 (31.1 to 40.7) |
| Pain at the injection site: Moderate | 27.4 (23.1 to 32.0) |
| Pain at the injection site: Severe | 0.2 (0.0 to 1.4) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.9) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Fever: >= 38.0 deg C | 1.4 (0.5 to 2.8) | 3.1 (1.3 to 6.0) |
| Fever: 38.0 to 38.4 deg C | 0.8 (0.2 to 2.0) | 1.9 (0.6 to 4.4) |
| Fever: >38.4 to 38.9 deg C | 0.6 (0.1 to 1.7) | 1.2 (0.2 to 3.3) |
| Fever: >38.9 to 40.0 deg C | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| Fever: >40.0 deg C | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| Fatigue: Any | 37.1 (32.9 to 41.4) | 37.7 (31.8 to 43.9) |
| Fatigue: Mild | 24.1 (20.4 to 28.0) | 23.8 (18.8 to 29.5) |
| Fatigue: Moderate | 13.0 (10.2 to 16.2) | 13.1 (9.2 to 17.8) |
| Fatigue: Severe | 0 (0.0 to 0.7) | 0.8 (0.1 to 2.8) |
| Fatigue: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| Headache: Any | 25.4 (21.7 to 29.4) | 25.8 (20.6 to 31.5) |
| Headache: Mild | 18.3 (15.0 to 21.9) | 19.2 (14.6 to 24.6) |
| Headache: Moderate | 6.8 (4.8 to 9.3) | 6.5 (3.9 to 10.3) |
| Headache: Severe | 0.4 (0.0 to 1.4) | 0 (0.0 to 1.4) |
| Headache: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| Chills: Any | 7.2 (5.1 to 9.8) | 9.6 (6.3 to 13.9) |
| Chills: Mild | 5.6 (3.8 to 8.0) | 6.5 (3.9 to 10.3) |
| Chills: Moderate | 1.4 (0.5 to 2.8) | 3.1 (1.3 to 6.0) |
| Chills: Severe | 0.2 (0.0 to 1.1) | 0 (0.0 to 1.4) |
| Chills: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| Vomiting: Any | 1.7 (0.8 to 3.3) | 2.3 (0.9 to 5.0) |
| Vomiting: Mild | 1.6 (0.7 to 3.0) | 1.9 (0.6 to 4.4) |
| Vomiting: Moderate | 0.2 (0.0 to 1.1) | 0.4 (0.0 to 2.1) |
| Vomiting: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| Vomiting: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| Diarrhea: Any | 6.2 (4.3 to 8.7) | 8.5 (5.4 to 12.5) |
| Diarrhea: Mild | 6.0 (4.1 to 8.4) | 8.1 (5.1 to 12.1) |
| Diarrhea: Moderate | 0.2 (0.0 to 1.1) | 0.4 (0.0 to 2.1) |
| Diarrhea: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| New or worsened muscle pain: Any | 11.7 (9.0 to 14.7) | 10.0 (6.6 to 14.3) |
| New or worsened muscle pain: Mild | 8.2 (5.9 to 10.9) | 7.7 (4.8 to 11.6) |
| New or worsened muscle pain: Moderate | 3.5 (2.1 to 5.5) | 2.3 (0.9 to 5.0) |
| New or worsened muscle pain: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| New or worsened joint pain: Any | 5.2 (3.5 to 7.5) | 6.9 (4.2 to 10.7) |
| New or worsened joint pain: Mild | 4.5 (2.9 to 6.6) | 5.4 (3.0 to 8.9) |
| New or worsened joint pain: Moderate | 0.8 (0.2 to 2.0) | 1.5 (0.4 to 3.9) |
| New or worsened joint pain: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 1.4) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age |
|---|---|
| Fever:>=38.0 deg C | 4.2 (2.6 to 6.4) |
| Fever: 8.0 to 38.4 deg C | 2.3 (1.2 to 4.1) |
| Fever: >38.4 to 38.9 deg C | 1.3 (0.5 to 2.7) |
| Fever: >38.9 to 40.0 deg C | 0.6 (0.1 to 1.8) |
| Fever: >40.0 deg C | 0 (0.0 to 0.8) |
| Fatigue: Any | 42.3 (37.8 to 46.9) |
| Fatigue: Mild | 26.3 (22.4 to 30.5) |
| Fatigue: Moderate | 15.6 (12.4 to 19.2) |
| Fatigue: Severe | 0.4 (0.1 to 1.5) |
| Fatigue: Grade 4 | 0 (0.0 to 0.8) |
| Headache: Any | 33.3 (29.0 to 37.7) |
| Headache: Mild | 22.9 (19.2 to 27.0) |
| Headache: Moderate | 10.3 (7.7 to 13.4) |
| Headache: Severe | 0 (0.0 to 0.8) |
| Headache: Grade 4 | 0 (0.0 to 0.8) |
| Chills: Any | 11.4 (8.7 to 14.6) |
| Chills: Mild | 8.6 (6.3 to 11.5) |
| Chills: Moderate | 2.5 (1.3 to 4.4) |
| Chills: Severe | 0.2 (0.0 to 1.2) |
| Chills: Grade 4 | 0 (0.0 to 0.8) |
| Vomiting: Any | 2.9 (1.6 to 4.9) |
| Vomiting: Mild | 2.7 (1.5 to 4.6) |
| Vomiting: Moderate | 0.2 (0.0 to 1.2) |
| Vomiting: Severe | 0 (0.0 to 0.8) |
| Vomiting: Grade 4 | 0 (0.0 to 0.8) |
| Diarrhea: Any | 9.1 (6.6 to 12.0) |
| Diarrhea: Mild | 6.9 (4.8 to 9.6) |
| Diarrhea: Moderate | 2.1 (1.0 to 3.8) |
| Diarrhea: Severe | 0 (0.0 to 0.8) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.8) |
| New or worsened muscle pain: Any | 26.3 (22.4 to 30.5) |
| New or worsened muscle pain: Mild | 14.7 (11.7 to 18.2) |
| New or worsened muscle pain: Moderate | 10.9 (8.3 to 14.1) |
| New or worsened muscle pain: Severe | 0.6 (0.1 to 1.8) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.8) |
| New or worsened joint pain: Any | 10.5 (7.9 to 13.6) |
| New or worsened joint pain: Mild | 5.1 (3.3 to 7.4) |
| New or worsened joint pain: Moderate | 5.5 (3.6 to 7.9) |
| New or worsened joint pain: Severe | 0 (0.0 to 0.8) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.8) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Fever: >=38.0 | 5.0 (3.3 to 7.3) | 0 (0.0 to 3.4) |
| Fever:38.0 to 38.4 deg C | 2.2 (1.1 to 3.9) | 0 (0.0 to 3.4) |
| Fever: >38.4 to 38.9 deg C | 1.8 (0.8 to 3.4) | 0 (0.0 to 3.4) |
| Fever: >38.9 to 40.0 deg C | 1.0 (0.3 to 2.3) | 0 (0.0 to 3.4) |
| Fever: >40.0 deg C | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| Fatigue: Any | 38.2 (33.9 to 42.7) | 29.0 (20.6 to 38.5) |
| Fatigue: Mild | 22.5 (18.9 to 26.5) | 15.9 (9.5 to 24.2) |
| Fatigue: Moderate | 15.5 (12.4 to 19.0) | 13.1 (7.3 to 21.0) |
| Fatigue: Severe | 0.2 (0.0 to 1.1) | 0 (0.0 to 3.4) |
| Fatigue: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| Headache: Any | 30.2 (26.2 to 34.4) | 20.6 (13.4 to 29.5) |
| Headache: Mild | 20.1 (16.7 to 23.9) | 14.0 (8.1 to 22.1) |
| Headache: Moderate | 9.9 (7.4 to 12.8) | 6.5 (2.7 to 13.0) |
| Headache: Severe | 0.2 (0.0 to 1.1) | 0 (0.0 to 3.4) |
| Headache: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| Chills: Any | 9.1 (6.7 to 11.9) | 7.5 (3.3 to 14.2) |
| Chills: Mild | 5.8 (3.9 to 8.3) | 6.5 (2.7 to 13.0) |
| Chills: Moderate | 3.2 (1.9 to 5.2) | 0.9 (0.0 to 5.1) |
| Chills: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| Chills: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| Vomiting: Any | 2.0 (1.0 to 3.7) | 3.7 (1.0 to 9.3) |
| Vomiting: Mild | 1.8 (0.8 to 3.4) | 2.8 (0.6 to 8.0) |
| Vomiting: Moderate | 0.2 (0.0 to 1.1) | 0.9 (0.0 to 5.1) |
| Vomiting: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| Vomiting: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| Diarrhea: Any | 7.4 (5.3 to 10.1) | 5.6 (2.1 to 11.8) |
| Diarrhea: Mild | 7.0 (5.0 to 9.7) | 5.6 (2.1 to 11.8) |
| Diarrhea: Moderate | 0.2 (0.0 to 1.1) | 0 (0.0 to 3.4) |
| Diarrhea: Severe | 0.2 (0.0 to 1.1) | 0 (0.0 to 3.4) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| New or worsened muscle pain: Any | 14.7 (11.7 to 18.1) | 11.2 (5.9 to 18.8) |
| New or worsened muscle pain: Mild | 9.3 (6.9 to 12.2) | 9.3 (4.6 to 16.5) |
| New or worsened muscle pain: Moderate | 5.4 (3.6 to 7.8) | 1.9 (0.2 to 6.6) |
| New or worsened muscle pain: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| New or worsened joint pain: Any | 6.4 (4.4 to 9.0) | 6.5 (2.7 to 13.0) |
| New or worsened joint pain: Mild | 4.2 (2.6 to 6.4) | 6.5 (2.7 to 13.0) |
| New or worsened joint pain: Moderate | 2.2 (1.1 to 3.9) | 0 (0.0 to 3.4) |
| New or worsened joint pain: Severe | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.7) | 0 (0.0 to 3.4) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age |
|---|---|
| Fever: >=38.0 deg C | 3.3 (1.9 to 5.5) |
| Fever:38.0 to 38.4 deg C | 1.6 (0.6 to 3.2) |
| Fever: >38.4 to 38.9 deg C | 1.3 (0.5 to 2.9) |
| Fever: >38.9 to 40.0 deg C | 0.4 (0.1 to 1.6) |
| Fever: >40.0 deg C | 0 (0.0 to 0.8) |
| Fatigue: Any | 36.4 (31.9 to 41.0) |
| Fatigue: Mild | 21.0 (17.3 to 25.1) |
| Fatigue: Moderate | 15.0 (11.8 to 18.6) |
| Fatigue: Severe | 0.4 (0.1 to 1.6) |
| Fatigue: Grade 4 | 0 (0.0 to 0.8) |
| Headache: Any | 33.3 (28.9 to 37.8) |
| Headache: Mild | 19.4 (15.9 to 23.4) |
| Headache: Moderate | 13.2 (10.2 to 16.7) |
| Headache: Severe | 0.7 (0.1 to 1.9) |
| Headache: Grade 4 | 0 (0.0 to 0.8) |
| Chills: Any | 11.2 (8.4 to 14.4) |
| Chills: Mild | 7.4 (5.1 to 10.2) |
| Chills: Moderate | 3.8 (2.2 to 6.0) |
| Chills: Severe | 0 (0.0 to 0.8) |
| Chills: Grade 4 | 0 (0.0 to 0.8) |
| Vomiting: Any | 2.2 (1.1 to 4.1) |
| Vomiting: Mild | 2.0 (0.9 to 3.8) |
| Vomiting: Moderate | 0.2 (0.0 to 1.2) |
| Vomiting: Severe | 0 (0.0 to 0.8) |
| Vomiting: Grade 4 | 0 (0.0 to 0.8) |
| Diarrhea: Any | 7.1 (4.9 to 9.9) |
| Diarrhea: Mild | 5.1 (3.3 to 7.6) |
| Diarrhea: Moderate | 1.8 (0.8 to 3.5) |
| Diarrhea: Severe | 0.2 (0.0 to 1.2) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.8) |
| New or worsened muscle pain: Any | 19.6 (16.1 to 23.6) |
| New or worsened muscle pain: Mild | 12.5 (9.6 to 15.9) |
| New or worsened muscle pain: Moderate | 6.9 (4.7 to 9.7) |
| New or worsened muscle pain: Severe | 0.2 (0.0 to 1.2) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.8) |
| New or worsened joint pain: Any | 6.7 (4.6 to 9.4) |
| New or worsened joint pain: Mild | 3.8 (2.2 to 6.0) |
| New or worsened joint pain: Moderate | 2.7 (1.4 to 4.6) |
| New or worsened joint pain: Severe | 0.2 (0.0 to 1.2) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.8) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Fever: >=38.0 deg C | 4.6 (2.7 to 7.1) | — |
| Fever:38.0 to 38.4 deg C | 2.5 (1.2 to 4.6) | — |
| Fever: >38.4 to 38.9 deg C | 1.0 (0.3 to 2.6) | — |
| Fever: >38.9 to 40.0 deg C | 1.0 (0.3 to 2.6) | — |
| Fever: >40.0 deg C | 0 (0.0 to 0.9) | — |
| Fatigue: Any | 38.8 (34.0 to 43.8) | — |
| Fatigue: Mild | 26.4 (22.1 to 31.0) | — |
| Fatigue: Moderate | 11.9 (8.9 to 15.5) | — |
| Fatigue: Severe | 0.5 (0.1 to 1.8) | — |
| Fatigue: Grade 4 | 0 (0.0 to 0.9) | — |
| Headache: Any | 23.6 (19.5 to 28.1) | — |
| Headache: Mild | 16.2 (12.7 to 20.3) | — |
| Headache: Moderate | 6.9 (4.6 to 9.8) | — |
| Headache: Severe | 0.5 (0.1 to 1.8) | — |
| Headache: Grade 4 | 0 (0.0 to 0.9) | — |
| Chills: Any | 8.9 (6.3 to 12.1) | — |
| Chills: Mild | 5.8 (3.7 to 8.6) | — |
| Chills: Moderate | 2.8 (1.4 to 4.9) | — |
| Chills: Severe | 0.3 (0.0 to 1.4) | — |
| Chills: Grade 4 | 0 (0.0 to 0.9) | — |
| Vomiting: Any | 1.8 (0.7 to 3.6) | — |
| Vomiting: Mild | 1.5 (0.6 to 3.3) | — |
| Vomiting: Moderate | 0.3 (0.0 to 1.4) | — |
| Vomiting: Severe | 0 (0.0 to 0.9) | — |
| Vomiting: Grade 4 | 0 (0.0 to 0.9) | — |
| Diarrhea: Any | 4.8 (2.9 to 7.4) | — |
| Diarrhea: Mild | 4.6 (2.7 to 7.1) | — |
| Diarrhea: Moderate | 0.3 (0.0 to 1.4) | — |
| Diarrhea: Severe | 0 (0.0 to 0.9) | — |
| Diarrhea: Grade 4 | 0 (0.0 to 0.9) | — |
| New or worsened muscle pain: Any | 18.5 (14.8 to 22.7) | — |
| New or worsened muscle pain: Mild | 10.2 (7.4 to 13.6) | — |
| New or worsened muscle pain: Moderate | 8.4 (5.8 to 11.6) | — |
| New or worsened muscle pain: Severe | 0 (0.0 to 0.9) | — |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.9) | — |
| New or worsened joint pain: Any | 5.8 (3.7 to 8.6) | — |
| New or worsened joint pain: Mild | 4.1 (2.3 to 6.5) | — |
| New or worsened joint pain: Moderate | 1.8 (0.7 to 3.6) | — |
| New or worsened joint pain: Severe | 0 (0.0 to 0.9) | — |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.9) | — |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age |
|---|---|
| Fever: >=38.0 deg C | 3.5 (1.9 to 5.7) |
| Fever: 8.0 to 38.4 deg C | 1.7 (0.7 to 3.5) |
| Fever: >38.4 to 38.9 deg C | 1.2 (0.4 to 2.9) |
| Fever: >38.9 to 40.0 deg C | 0.5 (0.1 to 1.8) |
| Fever: >40.0 deg C | 0 (0.0 to 0.9) |
| Fatigue: Any | 36.8 (32.1 to 41.7) |
| Fatigue: Mild | 21.7 (17.8 to 26.1) |
| Fatigue: Moderate | 14.8 (11.5 to 18.7) |
| Fatigue: Severe | 0.2 (0.0 to 1.4) |
| Fatigue: Grade 4 | 0 (0.0 to 0.9) |
| Headache: Any | 35.3 (30.7 to 40.2) |
| Headache: Mild | 23.0 (19.0 to 27.4) |
| Headache: Moderate | 11.6 (8.7 to 15.1) |
| Headache: Severe | 0.7 (0.2 to 2.1) |
| Headache: Grade 4 | 0 (0.0 to 0.9) |
| Chills: Any | 12.8 (9.7 to 16.5) |
| Chills: Mild | 8.4 (5.9 to 11.5) |
| Chills: Moderate | 4.4 (2.7 to 6.9) |
| Chills: Severe | 0 (0.0 to 0.9) |
| Chills: Grade 4 | 0 (0.0 to 0.9) |
| Vomiting: Any | 2.7 (1.4 to 4.8) |
| Vomiting: Mild | 2.2 (1.0 to 4.2) |
| Vomiting: Moderate | 0.5 (0.1 to 1.8) |
| Vomiting: Severe | 0 (0.0 to 0.9) |
| Vomiting: Grade 4 | 0 (0.0 to 0.9) |
| Diarrhea: Any | 4.4 (2.7 to 6.9) |
| Diarrhea: Mild | 4.0 (2.3 to 6.3) |
| Diarrhea: Moderate | 0.5 (0.1 to 1.8) |
| Diarrhea: Severe | 0 (0.0 to 0.9) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.9) |
| New or worsened muscle pain: Any | 18.8 (15.1 to 22.9) |
| New or worsened muscle pain: Mild | 10.6 (7.8 to 14.0) |
| New or worsened muscle pain: Moderate | 8.1 (5.7 to 11.3) |
| New or worsened muscle pain: Severe | 0 (0.0 to 0.9) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.9) |
| New or worsened joint pain: Any | 6.4 (4.2 to 9.3) |
| New or worsened joint pain: Mild | 4.0 (2.3 to 6.3) |
| New or worsened joint pain: Moderate | 2.5 (1.2 to 4.5) |
| New or worsened joint pain: Severe | 0 (0.0 to 0.9) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.9) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Troponin Group: 5 to <12 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=5 to <12 Years of Age | 7.1 (5.1 to 9.7) | 8.1 (5.1 to 12.1) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age |
|---|---|
| Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=12 to <16 Years of Age | 5.3 (3.5 to 7.7) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group: >=5 to <12 Years of Age | 11.5 (8.6 to 14.9) | — |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 3 to 1 month from dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age |
|---|---|
| Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group:>=12 to <16 Years of Age | 1.4 (0.5 to 3.0) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : Troponin Group: >=5 to <12 Years of Age | 0.2 (0.0 to 1.1) | 0 (0.0 to 1.4) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age |
|---|---|
| Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Troponin Group: >=12 to <16 Years of Age | 0.4 (0.0 to 1.5) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Phase 2/3: Troponin Group: BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: Troponin Group: >=5 to <12 Years of Age | 0.5 (0.1 to 1.7) | — |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age |
|---|---|
| Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3 : Troponin Group:>=12 to <16 Years of Age | 0 (0 to 0.8) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Redness: Any | 14.0 (12.8 to 15.3) | 5.9 (4.8 to 7.2) |
| Redness: Mild | 9.3 (8.3 to 10.3) | 5.1 (4.0 to 6.3) |
| Redness: Moderate | 4.7 (4.0 to 5.5) | 0.7 (0.4 to 1.3) |
| Redness: Severe | 0.0 (0.0 to 0.2) | 0.1 (0.0 to 0.5) |
| Redness: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Swelling: Any | 10.3 (9.3 to 11.5) | 3.0 (2.2 to 4.0) |
| Swelling: Mild | 5.7 (4.9 to 6.6) | 1.8 (1.2 to 2.6) |
| Swelling: Moderate | 4.6 (3.9 to 5.4) | 1.2 (0.7 to 1.9) |
| Swelling: Severe | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.2) |
| Swelling: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Pain at the injection site: Any | 72.9 (71.3 to 74.5) | 31.5 (29.2 to 33.9) |
| Pain at the injection site: Mild | 58.5 (56.7 to 60.2) | 28.3 (26.1 to 30.7) |
| Pain at the injection site: Moderate | 14.3 (13.1 to 15.6) | 3.1 (2.3 to 4.1) |
| Pain at the injection site: Severe | 0.2 (0.1 to 0.4) | 0 (0.0 to 0.2) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity),severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Redness: Any | 18.8 (17.4 to 20.2) | 5.2 (4.1 to 6.4) |
| Redness: Mild | 10.3 (9.2 to 11.4) | 3.7 (2.8 to 4.8) |
| Redness: Moderate | 8.4 (7.4 to 9.4) | 1.3 (0.8 to 2.0) |
| Redness: Severe | 0.1 (0.0 to 0.3) | 0.1 (0.0 to 0.5) |
| Redness: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Swelling: Any | 14.7 (13.5 to 16.0) | 2.7 (1.9 to 3.6) |
| Swelling: Mild | 8.1 (7.1 to 9.1) | 2.0 (1.3 to 2.8) |
| Swelling: Moderate | 6.6 (5.8 to 7.6) | 0.7 (0.4 to 1.3) |
| Swelling: Severe | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Swelling: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Pain at the injection site: Any | 71.2 (69.5 to 72.8) | 28.5 (26.3 to 30.9) |
| Pain at the injection site: Mild | 53.6 (51.8 to 55.4) | 25.6 (23.4 to 27.8) |
| Pain at the injection site: Moderate | 17.4 (16.1 to 18.8) | 2.9 (2.1 to 3.9) |
| Pain at the injection site: Severe | 0.2 (0.1 to 0.4) | 0.1 (0.0 to 0.4) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.4) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(\>=0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm),severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Redness: Any | 15.6 (14.2 to 17.2) | — |
| Redness: Mild | 9.4 (8.3 to 10.7) | — |
| Redness: Moderate | 6.1 (5.1 to 7.2) | — |
| Redness: Severe | 0.1 (0.0 to 0.3) | — |
| Redness: Grade 4 | 0 (0.0 to 0.2) | — |
| Swelling: Any | 12.6 (11.3 to 14.1) | — |
| Swelling: Mild | 6.5 (5.6 to 7.6) | — |
| Swelling: Moderate | 6.1 (5.1 to 7.2) | — |
| Swelling: Severe | 0 (0.0 to 0.2) | — |
| Swelling: Grade 4 | 0 (0.0 to 0.2) | — |
| Pain at the injection site: Any | 69.2 (67.3 to 71.1) | — |
| Pain at the injection site: Mild | 48.0 (46.0 to 50.1) | — |
| Pain at the injection site: Moderate | 20.9 (19.3 to 22.7) | — |
| Pain at the injection site: Severe | 0.3 (0.1 to 0.6) | — |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.2) | — |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe(prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Fever:>=38.0 deg C | 2.1 (1.6 to 2.6) | 1.4 (0.9 to 2.1) |
| Fever: 38.0 to 38.4 deg C | 1.2 (0.8 to 1.6) | 0.7 (0.3 to 1.2) |
| Fever: >38.4 to 38.9 deg C | 0.7 (0.4 to 1.1) | 0.6 (0.3 to 1.1) |
| Fever: >38.9 to 40.0 deg C | 0.1 (0.0 to 0.3) | 0.1 (0.0 to 0.5) |
| Fever: >40.0 deg C | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.2) |
| Fatigue: Any | 34.5 (32.8 to 36.2) | 32.4 (30.1 to 34.8) |
| Fatigue: Mild | 22.7 (21.2 to 24.2) | 21.1 (19.1 to 23.2) |
| Fatigue: Moderate | 11.6 (10.5 to 12.8) | 11.2 (9.6 to 12.9) |
| Fatigue: Severe | 0.2 (0.1 to 0.4) | 0.1 (0.0 to 0.5) |
| Fatigue: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Headache: Any | 22.7 (21.2 to 24.2) | 24.3 (22.2 to 26.5) |
| Headache: Mild | 17.1 (15.8 to 18.5) | 18.0 (16.1 to 20.0) |
| Headache: Moderate | 5.5 (4.7 to 6.4) | 5.9 (4.8 to 7.2) |
| Headache: Severe | 0.1 (0.0 to 0.3) | 0.4 (0.1 to 0.9) |
| Headache: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Chills: Any | 5.6 (4.8 to 6.5) | 5.5 (4.4 to 6.7) |
| Chills: Mild | 4.5 (3.8 to 5.2) | 4.5 (3.5 to 5.7) |
| Chills: Moderate | 1.2 (0.8 to 1.6) | 1.0 (0.5 to 1.6) |
| Chills: Severe | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Chills: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Vomiting: Any | 2.0 (1.6 to 2.6) | 2.0 (1.3 to 2.8) |
| Vomiting: Mild | 1.7 (1.3 to 2.2) | 1.8 (1.2 to 2.6) |
| Vomiting: Moderate | 0.4 (0.2 to 0.6) | 0.1 (0.0 to 0.5) |
| Vomiting: Severe | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Vomiting: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Diarrhea: Any | 6.4 (5.6 to 7.3) | 4.9 (3.9 to 6.1) |
| Diarrhea: Mild | 5.9 (5.1 to 6.8) | 4.7 (3.7 to 5.9) |
| Diarrhea: Moderate | 0.5 (0.2 to 0.8) | 0.2 (0.0 to 0.6) |
| Diarrhea: Severe | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| New or worsened muscle pain: Any | 9.3 (8.3 to 10.4) | 8.2 (6.9 to 9.7) |
| New or worsened muscle pain: Mild | 6.7 (5.8 to 7.6) | 6.3 (5.1 to 7.6) |
| New or worsened muscle pain: Moderate | 2.6 (2.1 to 3.3) | 2.0 (1.3 to 2.8) |
| New or worsened muscle pain: Severe | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.2) |
| New or worsened muscle pain:G4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| New or worsened joint pain:Any | 3.4 (2.8 to 4.1) | 4.6 (3.6 to 5.7) |
| New or worsened joint pain:Mild | 2.3 (1.8 to 2.9) | 3.7 (2.8 to 4.7) |
| New or worsened joint pain:Moderate | 1.1 (0.8 to 1.6) | 0.9 (0.5 to 1.5) |
| New or worsened joint pain:Severe | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| New or worsened joint pain: G4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 deg C; categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C,\>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Fever: Any | 6.3 (5.5 to 7.2) | 1.4 (0.9 to 2.1) |
| Fever: >=38.0 to 38.4 deg C | 3.3 (2.7 to 4.0) | 0.9 (0.5 to 1.5) |
| Fever: >38.4 to 38.9 deg C | 2.3 (1.8 to 2.9) | 0.3 (0.1 to 0.8) |
| Fever: >38.9 to 40.0 deg C | 0.7 (0.4 to 1.0) | 0.2 (0.0 to 0.6) |
| Fever: >40.0 deg C | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.2) |
| Fatigue: Any | 39.2 (37.4 to 40.9) | 25.2 (23.0 to 27.4) |
| Fatigue: Mild | 21.7 (20.3 to 23.2) | 15.1 (13.4 to 17.0) |
| Fatigue: Moderate | 16.6 (15.3 to 17.9) | 9.8 (8.3 to 11.4) |
| Fatigue: Severe | 0.9 (0.6 to 1.3) | 0.3 (0.1 to 0.7) |
| Fatigue: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Headache: Any | 28.4 (26.8 to 30.0) | 18.7 (16.7 to 20.7) |
| Headache: Mild | 18.8 (17.4 to 20.2) | 13.2 (11.6 to 15.0) |
| Headache: Moderate | 9.3 (8.3 to 10.4) | 5.4 (4.3 to 6.6) |
| Headache: Severe | 0.3 (0.1 to 0.5) | 0.1 (0.0 to 0.4) |
| Headache: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Chills: Any | 9.8 (8.8 to 10.9) | 4.3 (3.4 to 5.5) |
| Chills: Mild | 6.7 (5.8 to 7.6) | 3.4 (2.6 to 4.5) |
| Chills: Moderate | 3.1 (2.5 to 3.7) | 0.9 (0.5 to 1.5) |
| Chills: Severe | 0.1 (0.0 to 0.2) | 0.1 (0.0 to 0.4) |
| Chills: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Vomiting: Any | 2.0 (1.6 to 2.6) | 1.8 (1.2 to 2.6) |
| Vomiting: Mild | 1.8 (1.4 to 2.4) | 1.4 (0.9 to 2.2) |
| Vomiting: Moderate | 0.2 (0.1 to 0.4) | 0.3 (0.1 to 0.8) |
| Vomiting: Severe | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.2) |
| Vomiting: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| Diarrhea: Any | 5.4 (4.6 to 6.3) | 5.0 (4.0 to 6.2) |
| Diarrhea: Mild | 4.9 (4.1 to 5.7) | 4.6 (3.6 to 5.8) |
| Diarrhea: Moderate | 0.5 (0.3 to 0.8) | 0.4 (0.1 to 0.9) |
| Diarrhea: Severe | 0.1 (0.0 to 0.2) | 0 (0.0 to 0.2) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| New or worsened muscle pain:Any | 12.0 (10.9 to 13.2) | 6.8 (5.6 to 8.2) |
| New or worsened muscle pain:Mild | 8.0 (7.1 to 9.0) | 4.5 (3.5 to 5.6) |
| New or worsened muscle pain: Moderate | 4.0 (3.3 to 4.7) | 2.4 (1.7 to 3.3) |
| New or worsened muscle pain: Severe | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.2) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| New or worsened joint pain:Any | 5.2 (4.4 to 6.0) | 3.7 (2.9 to 4.8) |
| New or worsened joint pain:Mild | 3.4 (2.8 to 4.1) | 2.8 (2.0 to 3.7) |
| New or worsened joint pain: Moderate | 1.8 (1.4 to 2.4) | 1.0 (0.6 to 1.6) |
| New or worsened joint pain: Severe | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 deg C; categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C,\>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Fever: >=38.0 deg C | 6.8 (5.8 to 7.9) | — |
| Fever:38.0 to 38.4 deg C | 4.1 (3.3 to 5.0) | — |
| Fever: >38.4 to 38.9 deg C | 1.8 (1.3 to 2.4) | — |
| Fever: >38.9 to 40.0 deg C | 0.9 (0.5 to 1.4) | — |
| Fever: >40.0 deg C | 0.0 (0.0 to 0.2) | — |
| Fatigue: Any | 39.6 (37.6 to 41.7) | — |
| Fatigue: Mild | 21.0 (19.4 to 22.8) | — |
| Fatigue: Moderate | 17.3 (15.8 to 18.9) | — |
| Fatigue: Severe | 1.3 (0.9 to 1.8) | — |
| Fatigue: Grade 4 | 0 (0.0 to 0.2) | — |
| Headache: Any | 26.9 (25.1 to 28.8) | — |
| Headache: Mild | 16.2 (14.7 to 17.8) | — |
| Headache: Moderate | 10.3 (9.1 to 11.7) | — |
| Headache: Severe | 0.4 (0.2 to 0.8) | — |
| Headache: Grade 4 | 0 (0.0 to 0.2) | — |
| Chills: Any | 10.2 (9.0 to 11.5) | — |
| Chills: Mild | 6.2 (5.2 to 7.3) | — |
| Chills: Moderate | 3.9 (3.1 to 4.8) | — |
| Chills: Severe | 0.1 (0.0 to 0.4) | — |
| Chills: Grade 4 | 0 (0.0 to 0.2) | — |
| Vomiting: Any | 2.7 (2.1 to 3.4) | — |
| Vomiting: Mild | 2.2 (1.6 to 2.9) | — |
| Vomiting: Moderate | 0.4 (0.2 to 0.8) | — |
| Vomiting: Severe | 0.0 (0.0 to 0.2) | — |
| Vomiting: Grade 4 | 0 (0.0 to 0.2) | — |
| Diarrhea: Any | 4.6 (3.8 to 5.5) | — |
| Diarrhea: Mild | 4.3 (3.5 to 5.2) | — |
| Diarrhea: Moderate | 0.3 (0.1 to 0.6) | — |
| Diarrhea: Severe | 0.0 (0.0 to 0.2) | — |
| Diarrhea: Grade 4 | 0 (0.0 to 0.2) | — |
| New or worsened muscle pain: Any | 15.5 (14.0 to 17.0) | — |
| New or worsened muscle pain: Mild | 8.8 (7.7 to 10.0) | — |
| New or worsened muscle pain: Moderate | 6.5 (5.6 to 7.6) | — |
| New or worsened muscle pain: Severe | 0.1 (0.0 to 0.4) | — |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.2) | — |
| New or worsened joint pain: Any | 5.7 (4.8 to 6.7) | — |
| New or worsened joint pain: Mild | 3.5 (2.8 to 4.3) | — |
| New or worsened joint pain: Moderate | 2.2 (1.6 to 2.9) | — |
| New or worsened joint pain: Severe | 0.0 (0.0 to 0.2) | — |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.2) | — |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis\[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity),severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age |
|---|---|---|
| Redness: Any | 9.0 (7.9 to 10.3) | 8.4 (6.9 to 10.2) |
| Redness: Mild | 7.7 (6.7 to 8.9) | 7.5 (6.0 to 9.1) |
| Redness: Moderate | 1.2 (0.8 to 1.8) | 0.9 (0.4 to 1.6) |
| Redness: Severe | 0.0 (0.0 to 0.2) | 0.1 (0.0 to 0.5) |
| Redness: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.3) |
| Swelling: Any | 3.9 (3.2 to 4.8) | 3.1 (2.2 to 4.3) |
| Swelling: Mild | 3.4 (2.7 to 4.3) | 2.5 (1.7 to 3.6) |
| Swelling: Moderate | 0.5 (0.2 to 0.8) | 0.6 (0.2 to 1.2) |
| Swelling: Severe | 0 (0.0 to 0.2) | 0 (0.0 to 0.3) |
| Swelling: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.3) |
| Pain at the injection site: Any | 30.3 (28.4 to 32.2) | 20.6 (18.3 to 23.1) |
| Pain at the injection site: Mild | 28.1 (26.3 to 30.0) | 19.4 (17.2 to 21.8) |
| Pain at the injection site: Moderate | 2.2 (1.6 to 2.8) | 1.1 (0.6 to 1.9) |
| Pain at the injection site: Severe | 0 (0.0 to 0.2) | 0.1 (0.0 to 0.5) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.5) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age |
|---|---|---|
| Redness: Any | 11.2 (9.9 to 12.7) | 5.4 (4.1 to 6.9) |
| Redness: Mild | 9.6 (8.3 to 10.9) | 4.6 (3.4 to 6.1) |
| Redness: Moderate | 1.6 (1.1 to 2.3) | 0.8 (0.3 to 1.5) |
| Redness: Severe | 0.0 (0.0 to 0.3) | 0 (0.0 to 0.4) |
| Redness: Grade 4 | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
| Swelling: Any | 5.6 (4.7 to 6.7) | 2.0 (1.3 to 3.1) |
| Swelling: Mild | 4.4 (3.6 to 5.4) | 1.8 (1.1 to 2.8) |
| Swelling: Moderate | 1.2 (0.8 to 1.8) | 0.2 (0.0 to 0.7) |
| Swelling: Severe | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
| Swelling: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
| Pain at the injection site: Any | 30.5 (28.5 to 32.5) | 20.3 (17.9 to 22.9) |
| Pain at the injection site: Mild | 28.2 (26.3 to 30.2) | 19.4 (17.0 to 21.9) |
| Pain at the injection site: Moderate | 2.2 (1.6 to 2.9) | 0.9 (0.4 to 1.6) |
| Pain at the injection site: Severe | 0 (0.0 to 0.2) | 0.1 (0.0 to 0.5) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age |
|---|---|---|
| Redness: Any | 10.4 (8.4 to 12.7) | 4.8 (2.9 to 7.5) |
| Redness: Mild | 9.0 (7.1 to 11.2) | 4.0 (2.2 to 6.5) |
| Redness: Moderate | 1.4 (0.7 to 2.4) | 0.8 (0.2 to 2.3) |
| Redness: Severe | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| Redness: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| Swelling: Any | 3.1 (2.0 to 4.6) | 1.6 (0.6 to 3.4) |
| Swelling: Mild | 2.9 (1.8 to 4.3) | 1.6 (0.6 to 3.4) |
| Swelling: Moderate | 0.3 (0.0 to 0.9) | 0 (0.0 to 1.0) |
| Swelling: Severe | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| Swelling: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| Pain at the injection site: Any | 28.0 (24.9 to 31.3) | 12.8 (9.6 to 16.6) |
| Pain at the injection site: Mild | 26.0 (23.0 to 29.2) | 12.0 (8.9 to 15.7) |
| Pain at the injection site: Moderate | 2.0 (1.2 to 3.3) | 0.8 (0.2 to 2.3) |
| Pain at the injection site: Severe | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 deg C; categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C,\>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age |
|---|---|---|
| Fever:>=38.0 deg C | 5.5 (4.6 to 6.5) | 5.7 (4.4 to 7.2) |
| Fever: 38.0 to 38.4 deg C | 3.1 (2.4 to 3.8) | 2.6 (1.7 to 3.7) |
| Fever: >38.4 to 38.9 deg C | 1.5 (1.0 to 2.0) | 2.1 (1.3 to 3.1) |
| Fever: >38.9 to 40.0 deg C | 0.9 (0.6 to 1.4) | 1.0 (0.5 to 1.8) |
| Fever: >40.0 deg C | 0.1 (0.0 to 0.3) | 0 (0.0 to 0.3) |
| Fatigue: Any | 30.6 (28.7 to 32.5) | 31.9 (29.2 to 34.7) |
| Fatigue: Mild | 18.8 (17.2 to 20.4) | 19.5 (17.3 to 21.9) |
| Fatigue: Moderate | 11.5 (10.2 to 12.8) | 11.6 (9.9 to 13.6) |
| Fatigue: Severe | 0.4 (0.2 to 0.7) | 0.8 (0.4 to 1.5) |
| Fatigue: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.3) |
| Headache: Any | 5.1 (4.2 to 6.1) | 4.8 (3.7 to 6.2) |
| Headache: Mild | 3.9 (3.2 to 4.8) | 3.7 (2.7 to 5.0) |
| Headache: Moderate | 1.1 (0.7 to 1.6) | 1.0 (0.5 to 1.8) |
| Headache: Severe | 0 (0.0 to 0.2) | 0.1 (0.0 to 0.5) |
| Headache: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.3) |
| Chills: Any | 2.8 (2.1 to 3.5) | 2.9 (2.0 to 4.1) |
| Chills: Mild | 1.8 (1.3 to 2.4) | 2.0 (1.3 to 3.0) |
| Chills: Moderate | 0.9 (0.5 to 1.3) | 0.9 (0.4 to 1.6) |
| Chills: Severe | 0.1 (0.0 to 0.4) | 0.1 (0.0 to 0.5) |
| Chills: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.3) |
| Vomiting: Any | 3.5 (2.8 to 4.4) | 2.9 (2.0 to 4.1) |
| Vomiting: Mild | 2.9 (2.2 to 3.6) | 2.1 (1.3 to 3.1) |
| Vomiting: Moderate | 0.7 (0.4 to 1.1) | 0.9 (0.4 to 1.6) |
| Vomiting: Severe | 0 (0.0 to 0.2) | 0 (0.0 to 0.3) |
| Vomiting: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.3) |
| Diarrhea: Any | 8.6 (7.4 to 9.8) | 8.3 (6.8 to 10.0) |
| Diarrhea: Mild | 7.9 (6.8 to 9.0) | 7.4 (6.0 to 9.1) |
| Diarrhea: Moderate | 0.7 (0.4 to 1.1) | 0.9 (0.4 to 1.6) |
| Diarrhea: Severe | 0 (0.0 to 0.2) | 0 (0.0 to 0.3) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.3) |
| New or worsened muscle pain:Any | 2.6 (2.0 to 3.3) | 2.3 (1.5 to 3.4) |
| New or worsened muscle pain: Mild | 1.9 (1.4 to 2.6) | 1.7 (1.1 to 2.7) |
| New or worsened muscle pain: Moderate | 0.7 (0.4 to 1.1) | 0.5 (0.2 to 1.1) |
| New or worsened muscle pain: Severe | 0.0 (0.0 to 0.2) | 0.1 (0.0 to 0.5) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.3) |
| New or worsened joint pain: Any | 1.2 (0.8 to 1.7) | 1.8 (1.1 to 2.8) |
| New or worsened joint pain:Mild | 0.9 (0.6 to 1.4) | 1.4 (0.8 to 2.2) |
| New or worsened joint pain: Moderate | 0.2 (0.1 to 0.5) | 0.4 (0.1 to 1.0) |
| New or worsened joint pain:Severe | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.3) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.3) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age |
|---|---|---|
| Fever: >=38.0 deg C | 5.2 (4.3 to 6.2) | 5.8 (4.4 to 7.4) |
| Fever:38.0 to 38.4 deg C | 2.4 (1.8 to 3.2) | 2.2 (1.4 to 3.3) |
| Fever: >38.4 to 38.9 deg C | 1.5 (1.0 to 2.2) | 2.6 (1.7 to 3.8) |
| Fever: >38.9 to 40.0 deg C | 1.1 (0.7 to 1.6) | 0.9 (0.4 to 1.6) |
| Fever: >40.0 deg C | 0.1 (0.0 to 0.4) | 0.1 (0.0 to 0.5) |
| Fatigue: Any | 26.1 (24.2 to 28.0) | 24.3 (21.7 to 27.0) |
| Fatigue: Mild | 15.5 (13.9 to 17.1) | 14.7 (12.6 to 17.0) |
| Fatigue: Moderate | 10.2 (9.0 to 11.6) | 9.3 (7.6 to 11.2) |
| Fatigue: Severe | 0.4 (0.2 to 0.8) | 0.4 (0.1 to 1.0) |
| Fatigue: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
| Headache: Any | 4.6 (3.8 to 5.6) | 4.1 (3.0 to 5.5) |
| Headache: Mild | 3.5 (2.7 to 4.3) | 2.6 (1.7 to 3.8) |
| Headache: Moderate | 1.2 (0.7 to 1.7) | 1.4 (0.8 to 2.4) |
| Headache: Severe | 0 (0.0 to 0.2) | 0.1 (0.0 to 0.5) |
| Headache: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
| Chills: Any | 3.2 (2.5 to 4.0) | 2.8 (1.9 to 4.0) |
| Chills: Mild | 2.2 (1.6 to 2.9) | 2.2 (1.4 to 3.3) |
| Chills: Moderate | 1.0 (0.6 to 1.5) | 0.6 (0.2 to 1.3) |
| Chills: Severe | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
| Chills: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
| Vomiting: Any | 3.4 (2.6 to 4.2) | 3.4 (2.4 to 4.7) |
| Vomiting: Mild | 3.0 (2.3 to 3.8) | 2.9 (2.0 to 4.1) |
| Vomiting: Moderate | 0.4 (0.2 to 0.8) | 0.5 (0.2 to 1.1) |
| Vomiting: Severe | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
| Vomiting: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
| Diarrhea: Any | 6.8 (5.7 to 7.9) | 8.0 (6.4 to 9.8) |
| Diarrhea: Mild | 5.9 (4.9 to 7.0) | 7.1 (5.6 to 8.9) |
| Diarrhea: Moderate | 0.8 (0.5 to 1.3) | 0.8 (0.3 to 1.5) |
| Diarrhea: Severe | 0.1 (0.0 to 0.3) | 0.1 (0.0 to 0.5) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
| New or worsened muscle pain: Any | 2.6 (2.0 to 3.4) | 2.6 (1.7 to 3.8) |
| New or worsened muscle pain:Mild | 1.9 (1.3 to 2.6) | 2.0 (1.3 to 3.1) |
| New or worsened muscle pain: Moderate | 0.8 (0.4 to 1.2) | 0.6 (0.2 to 1.3) |
| New or worsened muscle pain: Severe | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
| New or worsened joint pain:Any | 1.2 (0.8 to 1.8) | 1.2 (0.6 to 2.0) |
| New or worsened joint pain:Mild | 0.9 (0.6 to 1.4) | 0.9 (0.4 to 1.6) |
| New or worsened joint pain: Moderate | 0.3 (0.1 to 0.7) | 0.3 (0.1 to 0.8) |
| New or worsened joint pain:Severe | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.2) | 0 (0.0 to 0.4) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 C; categorized as \>=38.0 deg C, 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age |
|---|---|---|
| Fever: >=38.0 deg C | 5.1 (3.7 to 6.9) | 5.6 (3.5 to 8.4) |
| Fever:38.0 to 38.4 deg C | 2.5 (1.5 to 3.8) | 2.1 (0.9 to 4.1) |
| Fever: >38.4 to 38.9 deg C | 1.8 (1.0 to 2.9) | 1.9 (0.8 to 3.8) |
| Fever: >38.9 to 40.0 deg C | 0.9 (0.4 to 1.8) | 1.6 (0.6 to 3.4) |
| Fever: >40.0 deg C | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| Fatigue: Any | 25.5 (22.5 to 28.7) | 24.3 (20.0 to 28.9) |
| Fatigue: Mild | 16.0 (13.5 to 18.8) | 14.7 (11.2 to 18.7) |
| Fatigue: Moderate | 9.2 (7.3 to 11.4) | 9.3 (6.6 to 12.7) |
| Fatigue: Severe | 0.3 (0.0 to 0.9) | 0.3 (0.0 to 1.5) |
| Fatigue: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| Headache: Any | 4.5 (3.2 to 6.2) | 4.0 (2.3 to 6.5) |
| Headache: Mild | 2.9 (1.8 to 4.3) | 2.9 (1.5 to 5.2) |
| Headache: Moderate | 1.6 (0.9 to 2.8) | 1.1 (0.3 to 2.7) |
| Headache: Severe | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| Headache: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| Chills: Any | 2.8 (1.7 to 4.2) | 2.7 (1.3 to 4.8) |
| Chills: Mild | 2.1 (1.3 to 3.4) | 2.4 (1.1 to 4.5) |
| Chills: Moderate | 0.5 (0.1 to 1.3) | 0.3 (0.0 to 1.5) |
| Chills: Severe | 0.1 (0.0 to 0.7) | 0 (0.0 to 1.0) |
| Chills: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| Vomiting: Any | 2.0 (1.2 to 3.3) | 4.3 (2.5 to 6.8) |
| Vomiting: Mild | 1.5 (0.8 to 2.6) | 2.9 (1.5 to 5.2) |
| Vomiting: Moderate | 0.5 (0.1 to 1.3) | 1.3 (0.4 to 3.1) |
| Vomiting: Severe | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| Vomiting: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| Diarrhea: Any | 4.9 (3.5 to 6.7) | 5.6 (3.5 to 8.4) |
| Diarrhea: Mild | 3.8 (2.6 to 5.4) | 4.5 (2.7 to 7.2) |
| Diarrhea: Moderate | 1.1 (0.5 to 2.1) | 1.1 (0.3 to 2.7) |
| Diarrhea: Severe | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| New or worsened muscle pain: Any | 1.9 (1.1 to 3.1) | 1.6 (0.6 to 3.4) |
| New or worsened muscle pain: Mild | 1.5 (0.8 to 2.6) | 1.3 (0.4 to 3.1) |
| New or worsened muscle pain: Moderate | 0.4 (0.1 to 1.1) | 0.3 (0.0 to 1.5) |
| New or worsened muscle pain: Severe | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
| New or worsened joint pain: Any | 1.1 (0.5 to 2.1) | 1.1 (0.3 to 2.7) |
| New or worsened joint pain: Mild | 0.9 (0.4 to 1.8) | 1.1 (0.3 to 2.7) |
| New or worsened joint pain: Moderate | 0.1 (0.0 to 0.7) | 0 (0.0 to 1.0) |
| New or worsened joint pain: Severe | 0.1 (0.0 to 0.7) | 0 (0.0 to 1.0) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 1.0) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age |
|---|---|---|
| Redness: Any | 10.7 (9.2 to 12.4) | 7.6 (5.7 to 9.8) |
| Redness: Mild | 9.8 (8.3 to 11.5) | 7.2 (5.4 to 9.3) |
| Redness: Moderate | 0.9 (0.5 to 1.5) | 0.4 (0.1 to 1.2) |
| Redness: Severe | 0 (0.0 to 0.3) | 0 (0.0 to 0.5) |
| Redness: Grade 4 | 0 (0.0 to 0.3) | 0 (0.0 to 0.5) |
| Swelling: Any | 3.8 (2.8 to 4.9) | 2.5 (1.5 to 4.0) |
| Swelling: Mild | 3.3 (2.5 to 4.4) | 2.2 (1.3 to 3.6) |
| Swelling: Moderate | 0.4 (0.2 to 0.9) | 0.3 (0.0 to 1.0) |
| Swelling: Severe | 0 (0.0 to 0.3) | 0 (0.0 to 0.5) |
| Swelling: Grade 4 | 0 (0.0 to 0.3) | 0 (0.0 to 0.5) |
| Tenderness at injection site: Any | 17.2 (15.3 to 19.3) | 12.6 (10.2 to 15.3) |
| Tenderness at injection site: Mild | 16.3 (14.4 to 18.3) | 11.5 (9.2 to 14.1) |
| Tenderness at injection site:Moderate | 0.8 (0.4 to 1.5) | 1.1 (0.5 to 2.2) |
| Tenderness at injection site:Severe | 0.1 (0.0 to 0.4) | 0 (0.0 to 0.5) |
| Tenderness at injection site: Grade 4 | 0 (0.0 to 0.3) | 0 (0.0 to 0.5) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate(hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age |
|---|---|---|
| Redness: Any | 9.9 (8.3 to 11.6) | 6.3 (4.6 to 8.4) |
| Redness: Mild | 9.1 (7.6 to 10.7) | 5.9 (4.2 to 7.9) |
| Redness: Moderate | 0.8 (0.4 to 1.5) | 0.5 (0.1 to 1.3) |
| Redness: Severe | 0 (0.0 to 0.3) | 0 (0.0 to 0.6) |
| Redness: Grade 4 | 0 (0.0 to 0.3) | 0 (0.0 to 0.6) |
| Swelling: Any | 4.1 (3.1 to 5.3) | 1.5 (0.7 to 2.7) |
| Swelling: Mild | 3.5 (2.6 to 4.6) | 1.4 (0.6 to 2.5) |
| Swelling: Moderate | 0.6 (0.3 to 1.2) | 0.2 (0.0 to 0.8) |
| Swelling: Severe | 0 (0.0 to 0.3) | 0 (0.0 to 0.6) |
| Swelling: Grade 4 | 0 (0.0 to 0.3) | 0 (0.0 to 0.6) |
| Tenderness at injection site: Any | 15.4 (13.5 to 17.5) | 9.3 (7.2 to 11.8) |
| Tenderness at injection site:Mild | 13.8 (12.0 to 15.8) | 7.7 (5.8 to 10.0) |
| Tenderness at injection site:Moderate | 1.6 (1.0 to 2.4) | 1.7 (0.8 to 2.9) |
| Tenderness at injection site:Severe | 0.1 (0.0 to 0.4) | 0 (0.0 to 0.6) |
| Tenderness at injection site: G4 | 0 (0.0 to 0.3) | 0 (0.0 to 0.6) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\>=0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[redness and swelling\] or exfoliative dermatitis \[redness\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age |
|---|---|---|
| Redness: Any | 7.2 (5.0 to 9.9) | 5.0 (2.5 to 8.7) |
| Redness: Mild | 5.0 (3.2 to 7.4) | 4.5 (2.2 to 8.1) |
| Redness: Moderate | 2.0 (0.9 to 3.7) | 0.5 (0.0 to 2.5) |
| Redness: Severe | 0.2 (0.0 to 1.2) | 0 (0.0 to 1.6) |
| Redness: Grade 4 | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
| Swelling: Any | 3.3 (1.8 to 5.3) | 2.3 (0.7 to 5.2) |
| Swelling: Mild | 2.0 (0.9 to 3.7) | 2.3 (0.7 to 5.2) |
| Swelling: Moderate | 1.3 (0.5 to 2.8) | 0 (0.0 to 1.6) |
| Swelling: Severe | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
| Swelling: Grade 4 | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
| Tenderness at injection site:Any | 14.7 (11.6 to 18.3) | 9.9 (6.3 to 14.6) |
| Tenderness at injection site:Mild | 13.0 (10.0 to 16.4) | 8.6 (5.2 to 13.0) |
| Tenderness at injection site: Moderate | 1.8 (0.8 to 3.4) | 1.4 (0.3 to 3.9) |
| Tenderness at injection site:Severe | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
| Tenderness at injection site: Grade 4 | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
Systemic events recorded in an e-diary \& at unscheduled clinical assessments up to Day 7 after Dose 1. Fever: oral temperature \>= 38.0 deg C; categorised as \>=38.0 to 38.4 deg C,\>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating),moderate (decreased oral intake),severe(refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age |
|---|---|---|
| Fever: >=38.0 deg C | 7.2 (5.9 to 8.7) | 7.4 (5.6 to 9.6) |
| Fever: 38.0 to 38.4 deg C | 3.4 (2.5 to 4.5) | 3.5 (2.3 to 5.1) |
| Fever: >38.4 to 38.9 deg C | 2.2 (1.5 to 3.1) | 2.5 (1.5 to 4.0) |
| Fever: >38.9 to 40.0 deg C | 1.5 (1.0 to 2.3) | 1.3 (0.6 to 2.4) |
| Fever: >40.0 deg C | 0.1 (0.0 to 0.4) | 0.1 (0.0 to 0.8) |
| Decreased appetite: Any | 22.7 (20.5 to 24.9) | 21.2 (18.3 to 24.5) |
| Decreased appetite: Mild | 12.4 (10.7 to 14.2) | 12.0 (9.7 to 14.7) |
| Decreased appetite: Moderate | 10.1 (8.6 to 11.8) | 8.9 (6.9 to 11.3) |
| Decreased appetite: Severe | 0.2 (0.0 to 0.6) | 0.3 (0.0 to 1.0) |
| Decreased appetite: Grade 4 | 0 (0.0 to 0.3) | 0 (0.0 to 0.5) |
| Drowsiness: Any | 27.8 (25.5 to 30.2) | 30.0 (26.7 to 33.6) |
| Drowsiness: Mild | 22.0 (19.8 to 24.2) | 22.7 (19.6 to 25.9) |
| Drowsiness: Moderate | 5.6 (4.5 to 6.9) | 6.9 (5.2 to 9.1) |
| Drowsiness: Severe | 0.2 (0.0 to 0.6) | 0.4 (0.1 to 1.2) |
| Drowsiness: Grade 4 | 0 (0.0 to 0.3) | 0 (0.0 to 0.5) |
| Irritability: Any | 51.0 (48.4 to 53.6) | 48.2 (44.4 to 51.9) |
| Irritability: Mild | 20.6 (18.6 to 22.8) | 18.3 (15.5 to 21.3) |
| Irritability: Moderate | 29.7 (27.3 to 32.1) | 29.6 (26.3 to 33.1) |
| Irritability: Severe | 0.7 (0.3 to 1.3) | 0.3 (0.0 to 1.0) |
| Irritability: Grade 4 | 0 (0.0 to 0.3) | 0 (0.0 to 0.5) |
Systemic events recorded in an e-diary \& at unscheduled clinical assessments up to Day 7 after Dose 2. Fever: oral temperature \>= 38.0 deg C; categorised as \>=38.0 to 38.4 deg C,\>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age |
|---|---|---|
| Fever: >=38.0 deg C | 7.6 (6.3 to 9.2) | 6.5 (4.7 to 8.6) |
| Fever: 38.0 to 38.4 deg C | 3.6 (2.7 to 4.8) | 3.6 (2.3 to 5.3) |
| Fever: >38.4 to 38.9 deg C | 2.0 (1.4 to 3.0) | 1.7 (0.8 to 2.9) |
| Fever: >38.9 to 40.0 deg C | 1.9 (1.2 to 2.8) | 1.2 (0.5 to 2.4) |
| Fever: >40.0 deg C | 0.1 (0.0 to 0.4) | 0 (0.0 to 0.6) |
| Decreased appetite: Any | 22.5 (20.3 to 24.9) | 19.4 (16.5 to 22.6) |
| Decreased appetite: Mild | 13.9 (12.1 to 15.9) | 11.3 (9.0 to 14.0) |
| Decreased appetite: Moderate | 8.1 (6.7 to 9.8) | 8.0 (6.0 to 10.3) |
| Decreased appetite: Severe | 0.5 (0.2 to 1.0) | 0.2 (0.0 to 0.8) |
| Decreased appetite: Grade 4 | 0 (0.0 to 0.3) | 0 (0.0 to 0.6) |
| Drowsiness: Any | 24.1 (21.8 to 26.5) | 21.4 (18.3 to 24.7) |
| Drowsiness: Mild | 17.8 (15.8 to 20.0) | 16.9 (14.1 to 19.9) |
| Drowsiness: Moderate | 6.0 (4.8 to 7.4) | 4.4 (2.9 to 6.2) |
| Drowsiness: Severe | 0.3 (0.1 to 0.8) | 0.2 (0.0 to 0.8) |
| Drowsiness: Grade 4 | 0 (0.0 to 0.3) | 0 (0.0 to 0.6) |
| Irritability: Any | 46.9 (44.2 to 49.6) | 41.4 (37.6 to 45.3) |
| Irritability: Mild | 18.5 (16.4 to 20.7) | 15.8 (13.1 to 18.8) |
| Irritability: Moderate | 27.8 (25.4 to 30.3) | 24.7 (21.5 to 28.2) |
| Irritability: Severe | 0.6 (0.3 to 1.2) | 0.9 (0.3 to 2.0) |
| Irritability: Grade 4 | 0 (0.0 to 0.3) | 0 (0.0 to 0.6) |
Systemic events recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 3. Fever: oral temperature \>= 38.0 deg C; categorised as \>=38.0 to 38.4 deg C,\>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe(disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age |
|---|---|---|
| Fever:>=38.0 deg C | 6.1 (4.1 to 8.7) | 5.9 (3.2 to 9.8) |
| Fever:38.0 to 38.4 deg C | 3.3 (1.8 to 5.3) | 3.2 (1.3 to 6.4) |
| Fever: >38.4 to 38.9 deg C | 1.3 (0.5 to 2.8) | 1.8 (0.5 to 4.5) |
| Fever: >38.9 to 40.0 deg C | 1.1 (0.4 to 2.5) | 0.9 (0.1 to 3.2) |
| Fever: >40.0 deg C | 0.4 (0.1 to 1.6) | 0 (0.0 to 1.6) |
| Decreased appetite: Any | 19.6 (16.0 to 23.5) | 13.1 (8.9 to 18.2) |
| Decreased appetite: Mild | 11.2 (8.5 to 14.5) | 7.2 (4.2 to 11.4) |
| Decreased appetite: Moderate | 7.5 (5.2 to 10.3) | 5.9 (3.2 to 9.8) |
| Decreased appetite: Severe | 0.9 (0.2 to 2.2) | 0 (0.0 to 1.6) |
| Decreased appetite: Grade 4 | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
| Drowsiness: Any | 21.5 (17.8 to 25.6) | 12.2 (8.2 to 17.2) |
| Drowsiness: Mild | 15.8 (12.6 to 19.5) | 9.0 (5.6 to 13.6) |
| Drowsiness: Moderate | 5.3 (3.4 to 7.7) | 2.7 (1.0 to 5.8) |
| Drowsiness: Severe | 0.4 (0.1 to 1.6) | 0.5 (0.0 to 2.5) |
| Drowsiness: Grade 4 | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
| Irritability: Any | 42.0 (37.4 to 46.7) | 36.9 (30.6 to 43.7) |
| Irritability: Mild | 15.8 (12.6 to 19.5) | 15.3 (10.8 to 20.7) |
| Irritability: Moderate | 25.7 (21.8 to 30.0) | 21.6 (16.4 to 27.6) |
| Irritability: Severe | 0.4 (0.1 to 1.6) | 0 (0.0 to 1.6) |
| Irritability: Grade 4 | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 2/3: BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age | 10.7 (9.6 to 11.9) | 9.8 (8.3 to 11.3) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age | 8.0 (7.0 to 9.2) | — |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=5 to <12 Years of Age | 0.3 (0.1 to 0.5) | 0.1 (0.0 to 0.5) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age | 0.4 (0.2 to 0.8) | — |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month from dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age | 13.1 (11.8 to 14.6) | 13.0 (11.1 to 15.0) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3:>=2 to <5 Years of Age | 4.5 (3.2 to 6.1) | 6.4 (4.2 to 9.3) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age | 0.5 (0.2 to 0.8) | 0.9 (0.4 to 1.6) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3:>=2 to <5 Years of Age | 0.3 (0.1 to 1.0) | 0 (0.0 to 0.9) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2 : >=6 Months to <2 Years of Age | 21.5 (19.4 to 23.7) | 19.9 (17.1 to 23.0) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3 : >=6 Months to <2 Years of Age | 10.4 (7.8 to 13.4) | 7.6 (4.6 to 11.7) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=6 Months to <2 Years of Age | 1.7 (1.1 to 2.5) | 2.4 (1.4 to 3.8) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age |
|---|---|---|
| Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age | 0.2 (0.0 to 1.1) | 0 (0.0 to 1.5) |
GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of the titers and the corresponding CIs (based on student t distribution). GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants of the age 16 to 25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section and GMR is reported under statistical analysis.
| Titer | Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age | Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years |
|---|---|---|
| Phase2/3:Geometric Mean Ratio(GMR)Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants>=5 to<12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort:1 Month After Dose 2:Participants Without Evidence of Infection | 1197.6 (1106.1 to 1296.6) | 1146.5 (1045.5 to 1257.2) |
Seroresponse is defined as achieving a \>=4 fold rise from baseline (before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
| Percentage of participants | Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age | Historical Cohort:C4591001 BNT162b2(30 mcg)16 to 25 Years |
|---|---|---|
| Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=5 to <12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection | 99.2 (97.3 to 99.9) | 99.2 (97.2 to 99.9) |
GMRs \& corresponding 2-sided CIs were calculated by exponentiating mean difference of logarithm of titers \& corresponding CIs(based on student t distribution).GMTs \& 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs(based on the Student t distribution).Assay results below LLOQ were set to 0.5\*LLOQ.Results include those from comparator group of C4591001(NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\& had no medical history of COVID-19 were also included.GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.EIP included all eligible randomized participants who received study intervention to which they were randomized,had a valid\&determinate immunogenicity result within 28-42 days after study vaccination,had no other important protocol deviations as determined by clinician.
| Titer | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years |
|---|---|---|
| Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection | 763.9 (688.5 to 847.5) | 1255.4 (1131.2 to 1393.3) |
Seroresponse is defined as achieving a \>=4-fold rise from baseline (before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
| Percentage of Participants | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years |
|---|---|---|
| Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection | 96.7 (93.6 to 98.6) | 97.6 (94.9 to 99.1) |
GMRs \& corresponding 2-sided CIs were calculated by exponentiating mean difference of logarithm of titers \& corresponding CIs(based on student t distribution).GMTs \& 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs(based on the Student t distribution).Assay results below LLOQ were set to 0.5\*LLOQ.Results include those from comparator group of C4591001(NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\& had no medical history of COVID-19 were also included.GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.EIP included all eligible randomized participants who received study intervention to which they were randomized,had a valid\&determinate immunogenicity result within 28-42 days after study vaccination,had no other important protocol deviations as determined by clinician.
| Titers | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years |
|---|---|---|
| Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection | 979.7 (893.2 to 1074.6) | 946.8 (850.8 to 1053.7) |
Seroresponse is defined as achieving a \>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
| Percentage of Participants | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years |
|---|---|---|
| Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort : 1 Month After Dose 2: Participants Without Evidence of Infection | 98.0 (95.3 to 99.3) | 96.2 (92.9 to 98.3) |
GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of logarithm of the titers and the corresponding CIs(based on student t distribution).GMTs \& 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Results include those from comparator group of C4591001 (NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection \& had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.
| Titers | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years |
|---|---|---|
| Phase 2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 3 in Participants Aged>=2 to<5Years Compared With Study C4591001 Phase2/3 16 to 25 Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection | 1535.2 (1388.2 to 1697.8) | 1180.0 (1066.6 to 1305.4) |
Seroresponse is defined as achieving a \>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse.Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years |
|---|---|---|
| Phase 2/3:Difference in Percentage of Participants With Seroresponse in 2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years of Age Historical Cohort: Participants Without Evidence of Infection | 100.0 (97.4 to 100.0) | 98.8 (95.8 to 99.9) |
GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of titers and the corresponding CIs (based on student t distribution). GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Results include those from comparator group of C4591001 (NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\& had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section \& GMR is reported under statistical analysis.
| Titers | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years |
|---|---|---|
| Phase2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose3 in Participants Aged 6Month to 2Year Compared With Study C4591001 Phase2/3 16 to 25Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection | 1406.5 (1211.3 to 1633.1) | 1180.0 (1066.6 to 1305.4) |
Seroresponse is defined as achieving a \>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \>=4\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
| Percentage of participants | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years |
|---|---|---|
| Phase 2/3:Difference in Percentage of Participants With Seroresponse in 6 Months to <2 Years (1 Month After Dose 3) Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort (1 Month After Dose 2): Participants Without Evidence of Infection | 100.0 (95.5 to 100.0) | 98.8 (95.8 to 99.9) |
GMT of SARS-CoV-2 neutralizing titer after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.
| Titer | Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age |
|---|---|
| Phase 1: Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=6 Months to <2 Years of Age: Participants Without Evidence of Infection | 1643.8 (1151.3 to 2347.1) |
GMT of SARS-CoV-2 neutralizing titers after the study vaccination was reported in this outcome measure. GMT and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution).Assay results below the LLOQ were set to 0.5\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.
| Titer | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age |
|---|---|---|
| Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=2 to <5 Years of Age: Participants Without Evidence of Infection | 1350.4 (973.1 to 1873.9) | 2059.5 (1679.1 to 2526.0) |
GMT of SARS-CoV-2 neutralizing titer after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.
| Titer | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age | Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age |
|---|---|---|---|---|
| Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=5 to <12 Years of Age: Participants Without Evidence of Infection | 4162.6 (2584.7 to 6704.0) | 4583.4 (2802.9 to 7494.8) | 242.1 (199.6 to 293.7) | — |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
| Titer | Phase 2/3:BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Pre-dose 1 | 10.1 (9.9 to 10.3) | 10.0 (10.0 to 10.0) |
| 1 Month after Dose 2 | 1197.6 (1106.1 to 1296.6) | 10.7 (9.7 to 11.8) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 \*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population (EIP) included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.
| Titer | Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Pre-Dose 3 | 271.0 (229.1 to 320.6) | — |
| 1 Month after Dose 3 | 2720.9 (2280.1 to 3247.0) | — |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 \*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19.
| Titer | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age |
|---|---|---|
| Pre-Dose 1 | 20.7 (20.3 to 21.2) | 20.5 (20.5 to 20.5) |
| Pre-Dose 3 | 401.1 (361.7 to 444.7) | 20.9 (20.1 to 21.8) |
| 1 Month after Dose 3 | 1535.2 (1388.2 to 1697.8) | 22.9 (19.5 to 26.8) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19.
| Titer | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age |
|---|---|---|
| Pre- Dose 1 | 20.8 (20.2 to 21.5) | 20.5 (20.5 to 20.5) |
| Pre-Dose 3 | 317.0 (268.8 to 373.9) | 24.2 (19.7 to 29.8) |
| 1 Month After Dose 3 | 1406.5 (1211.3 to 1633.1) | 22.3 (18.8 to 26.4) |
GMFR of SARS-CoV-2 neutralizing titers from dose 1 to 1 month after dose 2 were reported in this outcome measure. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Assay results below the LLOQ were set to 0.5\* LLOQ in the analysis.
| Fold rise | Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Phase 2/3: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Dose 1 to 1 Month After Dose 2: >=5 to 12 Years of Age: Participants Without Evidence of Infection | 118.2 (109.2 to 127.9) | 1.1 (1.0 to 1.2) |
GMFR of SARS-CoV-2 neutralizing titers from before Dose 3 to 1 month after Dose were reported in this outcome measure. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomized participants who received the study interventions to which they were randomized, had a valid and determined immunogenicity result within 28-42 days after Dose 3, and had no other important protocol deviations as determined by the clinicians.
| Fold rise | Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Phase 2/3:GMFR of SARS-CoV-2 Neutralizing Titers From Dose 3 to 1 Month After Dose 3: >=5 to 12 Years of Age: Participants Without Evidence of Infection | 10.0 (8.1 to 12.4) | — |
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs(based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 infection.Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.
| Fold rise | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age |
|---|---|---|
| Pre-Dose 3 | 19.2 (17.4 to 21.3) | 1.0 (1.0 to 1.1) |
| 1 Month after Dose 3 | 73.3 (66.3 to 81.1) | 1.1 (0.9 to 1.3) |
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection prior to the 1-month post-Dose 2.
| Fold rise | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age |
|---|---|---|
| Pre-Dose 3 | 15.4 (12.9 to 18.3) | 1.2 (1.0 to 1.5) |
| 1 Month after Dose 3 | 68.4 (58.2 to 80.4) | 1.1 (0.9 to 1.3) |
COVID-19 incidence from 7 days after dose 2 to prior to dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviations as determined by clinician on or before 7 days after Dose 2.
| Events per 1000 person-years | Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=5 to <12 Years of Age | 16.920 | 143.836 |
COVID-19 incidence from 7 days after dose 2 to prior to dose 3 with or without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviation as determined by clinician on or before 7 days after Dose 2.
| Events per 1000 person-years | Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age |
|---|---|---|
| Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=5 to <12 Years of Age | 18.377 | 128.834 |
COVID-19 incidence from 7 days after dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by clinician on or before 7 days after Dose 3.
| Events per 1000 person-years | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <5 Years of Age | Phase 2/3: Placebo: 6 Months to <5 Years of Age |
|---|---|---|
| Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=6 Months to <5 Years of Age | 104.839 | 388.889 |
COVID-19 incidence from 7 days after dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by the clinician on or before 7 days after Dose 3.
| Events per 1000 person-years | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <5 Years of Age | Phase 2/3: Placebo: 6 Months to <5 Years of Age |
|---|---|---|
| Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=6 Months to <5 Years of Age | 93.960 | 343.284 |
Collected over Other AEs (non-SAEs): from Dose(D) 1 to 1 month after D2 and D3 to 1 month after D3. Local reactions/systemic events: Day 1 to 7 after each dose. SAEs: From D1 to 6 months after D2 and from D3 to 6 months after D3 (maximum up to 28.5 months for Phase 1, 30.5 months for Phase 2/3 during blinded follow-up period and 24.2 months for Phase 2/3 during OL period). 'OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D2)': SAEs: From D2 to 6 months after D2 and non-SAEs: from D1 to 1 month after D2. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D1-D2) | 0/16 (0%) | 0/16 (0%) | 10/16 (62.5%) |
| Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D3) | 0/15 (0%) | 0/15 (0%) | 7/15 (46.7%) |
| Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2) | 0/16 (0%) | 0/16 (0%) | 10/16 (62.5%) |
| Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2) | 0/32 (0%) | 0/32 (0%) | 32/32 (100%) |
| Phase 1: BNT162b2 10 mcg: 2 to <5 Years of Age (D3) | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Ph1:2-<5Y:D3: BNT162b2 3 mcg (D3) | 0/27 (0%) | 0/27 (0%) | 17/27 (63%) |
| Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2) | 0/16 (0%) | 0/16 (0%) | 16/16 (100%) |
| Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age (D1-D2) | 0/16 (0%) | 0/16 (0%) | 16/16 (100%) |
| Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age (D1-D2) | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age (D1-D2) | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3) | 0/38 (0%) | 0/38 (0%) | 35/38 (92.1%) |
| Phase 1:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3) | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Blinded Phase (BP): Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2) | 0/1,458 (0%) | 24/1,458 (1.6%) | 1,154/1,458 (79.1%) |
| BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age (D1-D2) | 0/718 (0%) | 17/718 (2.4%) | 550/718 (76.6%) |
| BP: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3) | 0/1,324 (0%) | 1/1,324 (0.1%) | 267/1,324 (20.2%) |
| BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age(D3) | 0/237 (0%) | 0/237 (0%) | 119/237 (50.2%) |
| BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2) | 0/2,368 (0%) | 11/2,368 (0.5%) | 1,661/2,368 (70.1%) |
| BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D1-D2) | 0/1,173 (0%) | 10/1,173 (0.9%) | 778/1,173 (66.3%) |
| BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3) | 0/1,889 (0%) | 3/1,889 (0.2%) | 398/1,889 (21.1%) |
| BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D3) | 0/405 (0%) | 0/405 (0%) | 152/405 (37.5%) |
| BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2) | 0/3,109 (0%) | 8/3,109 (0.3%) | 2,821/3,109 (90.7%) |
| BP: Phase 2/3: Placebo: 5 to <12 Years of Age (D1-D2) | 0/1,538 (0%) | 3/1,538 (0.2%) | 1,083/1,538 (70.4%) |
| BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3) | 0/2,410 (0%) | 10/2,410 (0.4%) | 1,794/2,410 (74.4%) |
| BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D1-D2) | 0/518 (0%) | 1/518 (0.2%) | 442/518 (85.3%) |
| BP: Phase 2/3:Troponin Group:Placebo:5 to <12 Years of Age (D1-D2) | 0/260 (0%) | 0/260 (0%) | 163/260 (62.7%) |
| BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D3) | 0/418 (0%) | 2/418 (0.5%) | 319/418 (76.3%) |
| BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D1-D2) | 0/487 (0%) | 2/487 (0.4%) | 414/487 (85%) |
| BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D3) | 0/433 (0%) | 0/433 (0%) | 285/433 (65.8%) |
| OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2) | 0/581 (0%) | 5/581 (0.9%) | 52/581 (9%) |
| OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3) | 0/534 (0%) | 11/534 (2.1%) | 6/534 (1.1%) |
| OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2) | 0/706 (0%) | 2/706 (0.3%) | 31/706 (4.4%) |
| OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3) | 0/581 (0%) | 6/581 (1%) | 8/581 (1.4%) |
| OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2) | 0/1,262 (0%) | 4/1,262 (0.3%) | 159/1,262 (12.6%) |
| OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2) | 0/243 (0%) | 2/243 (0.8%) | 52/243 (21.4%) |
| OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3) | 0/957 (0%) | 3/957 (0.3%) | 75/957 (7.8%) |
| OL: Phase 2/3: BNT162b2 (30 mcg): 5 to <12 Years of Age (D3) | 0/91 (0%) | 2/91 (2.2%) | 0/91 (0%) |
| OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D3) | 0/202 (0%) | 0/202 (0%) | 20/202 (9.9%) |
| OL: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3) | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D3) | 0/113 (0%) | 0/113 (0%) | 3/113 (2.7%) |
| OL: Phase 2/3: BNT162b2 (10 mcg/30 mcg): 5 to <12 Years of Age (D3) | 0/145 (0%) | 2/145 (1.4%) | 17/145 (11.7%) |
| BP: Phase 2/3: BNT162b2 (3 mcg/10 mcg): 2 to <5 Years of Age (D3) | 0/204 (0%) | 1/204 (0.5%) | 13/204 (6.4%) |
| OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2) | 0/81 (0%) | 0/81 (0%) | 10/81 (12.3%) |
| OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D2) | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Event | Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D1-D2) | Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D3) | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2) | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2) | Phase 1: BNT162b2 10 mcg: 2 to <5 Years of Age (D3) | Ph1:2-<5Y:D3: BNT162b2 3 mcg (D3) | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2) | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age (D1-D2) | Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age (D1-D2) | Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age (D1-D2) | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3) | Phase 1:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3) | Blinded Phase (BP): Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2) | BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age (D1-D2) | BP: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3) | BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age(D3) | BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2) | BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D1-D2) | BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3) | BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D3) | BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2) | BP: Phase 2/3: Placebo: 5 to <12 Years of Age (D1-D2) | BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3) | BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D1-D2) | BP: Phase 2/3:Troponin Group:Placebo:5 to <12 Years of Age (D1-D2) | BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D3) | BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D1-D2) | BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2) | OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2) | OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2) | OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2) | OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (30 mcg): 5 to <12 Years of Age (D3) | OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D3) | OL: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (10 mcg/30 mcg): 5 to <12 Years of Age (D3) | BP: Phase 2/3: BNT162b2 (3 mcg/10 mcg): 2 to <5 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2) | OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PharyngitisInfections and infestations | 0/16 | 0/15 | 0/16 | 0/32 | 0/13 | 0/27 | 0/16 | 0/16 | 0/4 | 0/12 | 0/38 | 0/2 | 0/1458 | 0/718 | 0/1324 | 0/237 | 0/2368 | 0/1173 | 0/1889 | 0/405 | 0/3109 | 0/1538 | 0/2410 | 0/518 | 0/260 | 0/418 | 0/487 | 0/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 1/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Conversion disorderPsychiatric disorders | 0/16 | 0/15 | 0/16 | 0/32 | 0/13 | 0/27 | 0/16 | 0/16 | 0/4 | 0/12 | 0/38 | 0/2 | 0/1458 | 0/718 | 0/1324 | 0/237 | 0/2368 | 0/1173 | 0/1889 | 0/405 | 0/3109 | 0/1538 | 0/2410 | 0/518 | 0/260 | 0/418 | 0/487 | 0/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 1/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Addison's diseaseEndocrine disorders | 0/16 | 0/15 | 0/16 | 0/32 | 0/13 | 0/27 | 0/16 | 0/16 | 0/4 | 0/12 | 0/38 | 0/2 | 0/1458 | 0/718 | 0/1324 | 0/237 | 0/2368 | 0/1173 | 0/1889 | 0/405 | 0/3109 | 0/1538 | 0/2410 | 0/518 | 0/260 | 0/418 | 0/487 | 0/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 1/145 | 0/204 | 0/81 | 0/13 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 0/16 | 0/15 | 0/16 | 0/32 | 0/13 | 0/27 | 0/16 | 0/16 | 0/4 | 0/12 | 0/38 | 0/2 | 0/1458 | 0/718 | 0/1324 | 0/237 | 0/2368 | 0/1173 | 0/1889 | 0/405 | 0/3109 | 0/1538 | 0/2410 | 0/518 | 0/260 | 0/418 | 0/487 | 0/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 1/145 | 0/204 | 0/81 | 0/13 |
| SeizureNervous system disorders | 0/16 | 0/15 | 0/16 | 0/32 | 0/13 | 0/27 | 0/16 | 0/16 | 0/4 | 0/12 | 0/38 | 0/2 | 1/1458 | 0/718 | 0/1324 | 0/237 | 0/2368 | 0/1173 | 0/1889 | 0/405 | 0/3109 | 0/1538 | 1/2410 | 0/518 | 0/260 | 0/418 | 0/487 | 0/433 | 0/581 | 1/534 | 0/706 | 0/581 | 0/1262 | 1/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 1/204 | 0/81 | 0/13 |
| BronchiolitisInfections and infestations | 0/16 | 0/15 | 0/16 | 0/32 | 0/13 | 0/27 | 0/16 | 0/16 | 0/4 | 0/12 | 0/38 | 0/2 | 3/1458 | 3/718 | 0/1324 | 0/237 | 0/2368 | 1/1173 | 0/1889 | 0/405 | 0/3109 | 0/1538 | 0/2410 | 0/518 | 0/260 | 0/418 | 0/487 | 0/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| PyelonephritisInfections and infestations | 0/16 | 0/15 | 0/16 | 0/32 | 0/13 | 0/27 | 0/16 | 0/16 | 0/4 | 0/12 | 0/38 | 0/2 | 0/1458 | 0/718 | 0/1324 | 0/237 | 0/2368 | 0/1173 | 0/1889 | 0/405 | 0/3109 | 0/1538 | 0/2410 | 0/518 | 0/260 | 0/418 | 0/487 | 0/433 | 0/581 | 0/534 | 0/706 | 1/581 | 0/1262 | 1/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 0/16 | 0/15 | 0/16 | 0/32 | 0/13 | 0/27 | 0/16 | 0/16 | 0/4 | 0/12 | 0/38 | 0/2 | 5/1458 | 1/718 | 1/1324 | 0/237 | 0/2368 | 0/1173 | 0/1889 | 0/405 | 0/3109 | 0/1538 | 0/2410 | 0/518 | 0/260 | 0/418 | 0/487 | 0/433 | 0/581 | 2/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| CyanosisVascular disorders | 0/16 | 0/15 | 0/16 | 0/32 | 0/13 | 0/27 | 0/16 | 0/16 | 0/4 | 0/12 | 0/38 | 0/2 | 0/1458 | 2/718 | 0/1324 | 0/237 | 0/2368 | 0/1173 | 0/1889 | 0/405 | 0/3109 | 0/1538 | 0/2410 | 0/518 | 0/260 | 0/418 | 0/487 | 0/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Sickle cell anaemia with crisisBlood and lymphatic system disorders | 0/16 | 0/15 | 0/16 | 0/32 | 0/13 | 0/27 | 0/16 | 0/16 | 0/4 | 0/12 | 0/38 | 0/2 | 0/1458 | 0/718 | 0/1324 | 0/237 | 0/2368 | 0/1173 | 0/1889 | 0/405 | 0/3109 | 0/1538 | 0/2410 | 0/518 | 0/260 | 1/418 | 0/487 | 0/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Event | Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D1-D2) | Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D3) | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2) | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2) | Phase 1: BNT162b2 10 mcg: 2 to <5 Years of Age (D3) | Ph1:2-<5Y:D3: BNT162b2 3 mcg (D3) | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2) | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age (D1-D2) | Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age (D1-D2) | Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age (D1-D2) | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3) | Phase 1:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3) | Blinded Phase (BP): Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2) | BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age (D1-D2) | BP: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3) | BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age(D3) | BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2) | BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D1-D2) | BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3) | BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D3) | BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2) | BP: Phase 2/3: Placebo: 5 to <12 Years of Age (D1-D2) | BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3) | BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D1-D2) | BP: Phase 2/3:Troponin Group:Placebo:5 to <12 Years of Age (D1-D2) | BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D3) | BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D1-D2) | BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2) | OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2) | OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2) | OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2) | OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (30 mcg): 5 to <12 Years of Age (D3) | OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D3) | OL: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (10 mcg/30 mcg): 5 to <12 Years of Age (D3) | BP: Phase 2/3: BNT162b2 (3 mcg/10 mcg): 2 to <5 Years of Age (D3) | OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2) | OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 0/16 | 0/15 | 0/16 | 4/32 | 0/13 | 0/27 | 2/16 | 5/16 | 4/4 | 1/12 | 3/38 | 0/2 | 0/1458 | 0/718 | 0/1324 | 0/237 | 106/2368 | 50/1173 | 15/1889 | 6/405 | 561/3109 | 192/1538 | 350/2410 | 81/518 | 31/260 | 73/418 | 167/487 | 76/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Fatigue (FATIGUE)General disorders | 0/16 | 0/15 | 5/16 | 23/32 | 0/13 | 8/27 | 14/16 | 13/16 | 4/4 | 10/12 | 15/38 | 1/2 | 0/1458 | 0/718 | 0/1324 | 0/237 | 977/2368 | 487/1173 | 202/1889 | 91/405 | 1614/3109 | 641/1538 | 897/2410 | 221/518 | 105/260 | 153/418 | 255/487 | 149/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Injection site erythema (REDNESS)General disorders | 3/16 | 2/15 | 0/16 | 9/32 | 0/13 | 1/27 | 8/16 | 3/16 | 4/4 | 3/12 | 11/38 | 0/2 | 237/1458 | 83/718 | 33/1324 | 11/237 | 379/2368 | 136/1173 | 83/1889 | 18/405 | 806/3109 | 148/1538 | 354/2410 | 92/518 | 17/260 | 67/418 | 12/487 | 14/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Injection site pain (PAIN)General disorders | 0/16 | 0/15 | 7/16 | 21/32 | 0/13 | 9/27 | 14/16 | 15/16 | 4/4 | 11/12 | 33/38 | 1/2 | 0/1458 | 0/718 | 0/1324 | 0/237 | 998/2368 | 357/1173 | 222/1889 | 48/405 | 2603/3109 | 661/1538 | 1568/2410 | 397/518 | 79/260 | 273/418 | 384/487 | 257/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Pyrexia (FEVER)General disorders | 2/16 | 1/15 | 1/16 | 9/32 | 0/13 | 0/27 | 3/16 | 4/16 | 4/4 | 4/12 | 1/38 | 0/2 | 184/1458 | 87/718 | 28/1324 | 13/237 | 224/2368 | 121/1173 | 41/1889 | 21/405 | 243/3109 | 40/1538 | 154/2410 | 16/518 | 8/260 | 18/418 | 33/487 | 14/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Headache (HEADACHE)Nervous system disorders | 0/16 | 0/15 | 2/16 | 8/32 | 0/13 | 1/27 | 10/16 | 11/16 | 3/4 | 6/12 | 13/38 | 1/2 | 0/1458 | 0/718 | 0/1324 | 0/237 | 191/2368 | 86/1173 | 36/1889 | 15/405 | 1193/3109 | 506/1538 | 610/2410 | 163/518 | 77/260 | 93/418 | 228/487 | 143/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Chills (CHILLS)General disorders | 0/16 | 0/15 | 1/16 | 3/32 | 0/13 | 0/27 | 5/16 | 7/16 | 3/4 | 5/12 | 6/38 | 1/2 | 0/1458 | 0/718 | 0/1324 | 0/237 | 125/2368 | 59/1173 | 22/1889 | 10/405 | 413/3109 | 129/1538 | 231/2410 | 50/518 | 31/260 | 35/418 | 88/487 | 52/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Injection site swelling (SWELLING)General disorders | 1/16 | 1/15 | 0/16 | 4/32 | 0/13 | 0/27 | 8/16 | 3/16 | 3/4 | 1/12 | 5/38 | 0/2 | 94/1458 | 26/718 | 15/1324 | 5/237 | 182/2368 | 53/1173 | 25/1889 | 6/405 | 622/3109 | 78/1538 | 286/2410 | 69/518 | 14/260 | 50/418 | 27/487 | 12/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Irritability (IRRITABILITY)Psychiatric disorders | 8/16 | 4/15 | 0/16 | 0/32 | 0/13 | 0/27 | 0/16 | 0/16 | 0/4 | 0/12 | 0/38 | 0/2 | 932/1458 | 431/718 | 191/1324 | 82/237 | 0/2368 | 0/1173 | 0/1889 | 0/405 | 0/3109 | 0/1538 | 0/2410 | 0/518 | 0/260 | 0/418 | 0/487 | 0/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
| Diarrhea (DIARRHEA)Gastrointestinal disorders | 0/16 | 0/15 | 1/16 | 5/32 | 0/13 | 1/27 | 1/16 | 1/16 | 2/4 | 0/12 | 0/38 | 0/2 | 0/1458 | 0/718 | 0/1324 | 0/237 | 305/2368 | 160/1173 | 39/1889 | 21/405 | 320/3109 | 138/1538 | 104/2410 | 40/518 | 26/260 | 19/418 | 66/487 | 18/433 | 0/581 | 0/534 | 0/706 | 0/581 | 0/1262 | 0/243 | 0/957 | 0/91 | 0/202 | 0/9 | 0/113 | 0/145 | 0/204 | 0/81 | 0/13 |
Safety set included all participants who received at least 1 dose of the study intervention. Participants were analyzed according to the treatment which they received.
| Age, Customized(Participants) | Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | Phase 1: 5 to <12 Years 30/30 mcg | Phase 1: 5 to <12 Years 30/10 mcg | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age | Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age | Phase 2/3:Troponin Group:BNT162b2(10 mcg):5 to<12 Years of Age | Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age | Phase 2/3:Troponin Group:BNT162b2(30 mcg):12 to<16years of Age | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infants and toddlers (28 days-23 months) | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 1458 | 718 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2192 |
| Children (2-11 years) | 0 | 16 | 32 | 16 | 16 | 4 | 12 | 0 | 0 | 2368 | 1173 | 3109 | 1538 | 518 | 260 | 0 | 9062 |
| Adolescents (12-17 years) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 487 | 487 |
| Sex: Female, Male(Participants) | Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | Phase 1: 5 to <12 Years 30/30 mcg | Phase 1: 5 to <12 Years 30/10 mcg | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age | Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age | Phase 2/3:Troponin Group:BNT162b2(10 mcg):5 to<12 Years of Age | Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age | Phase 2/3:Troponin Group:BNT162b2(30 mcg):12 to<16years of Age | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 6 | 7 | 13 | 11 | 6 | 1 | 6 | 728 | 372 | 1197 | 570 | 1500 | 759 | 252 | 120 | 216 | 5764 |
| Male | 10 | 9 | 19 | 5 | 10 | 3 | 6 | 730 | 346 | 1171 | 603 | 1609 | 779 | 266 | 140 | 271 | 5977 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | Phase 1: 5 to <12 Years 30/30 mcg | Phase 1: 5 to <12 Years 30/10 mcg | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age | Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age | Phase 2/3:Troponin Group:BNT162b2(10 mcg):5 to<12 Years of Age | Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age | Phase 2/3:Troponin Group:BNT162b2(30 mcg):12 to<16years of Age | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 1 | 2 | 0 | 2 | 0 | 248 | 93 | 426 | 193 | 526 | 265 | 52 | 34 | 422 | 2267 |
| Not Hispanic or Latino | 13 | 16 | 31 | 14 | 16 | 2 | 12 | 1205 | 620 | 1934 | 979 | 2579 | 1273 | 466 | 226 | 65 | 9451 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 8 | 1 | 4 | 0 | 0 | 0 | 0 | 23 |
| Race (NIH/OMB)(Participants) | Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age | Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age | Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | Phase 1: 5 to <12 Years 30/30 mcg | Phase 1: 5 to <12 Years 30/10 mcg | Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age | Phase 2/3: Placebo: 6 Months to <2 Years of Age | Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age | Phase 2/3: Placebo: 2 to <5 Years of Age | Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age | Phase 2/3: Placebo: 5 to <12 Years of Age | Phase 2/3:Troponin Group:BNT162b2(10 mcg):5 to<12 Years of Age | Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age | Phase 2/3:Troponin Group:BNT162b2(30 mcg):12 to<16years of Age | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 4 | 1 | 4 | 4 | 13 | 4 | 1 | 1 | 209 | 242 |
| Asian | 1 | 1 | 2 | 2 | 2 | 0 | 1 | 101 | 51 | 147 | 92 | 256 | 118 | 49 | 16 | 4 | 843 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 10 | 0 | 0 | 0 | 0 | 13 |
| Black or African American | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 73 | 34 | 138 | 71 | 179 | 101 | 19 | 11 | 40 | 671 |
| White | 13 | 12 | 25 | 11 | 13 | 4 | 10 | 1126 | 562 | 1870 | 913 | 2404 | 1199 | 425 | 219 | 228 | 9034 |
| More than one race | 2 | 3 | 2 | 0 | 1 | 0 | 1 | 149 | 65 | 189 | 86 | 235 | 106 | 23 | 13 | 1 | 876 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 18 | 6 | 12 | 10 | 1 | 0 | 5 | 62 |
Showing the first 100 of 128 sites across 6 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Oct 2023, 30 months.
Results were first posted in May 2026, 2 years 7 months after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 30 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Biological Products · BNT162 Vaccine